Category: For physicians

  • Dr. Gurpreet Singh Padda presenting the title card Wash Out the Lesion, Don't Jam the Signal, The Pained Brain, Chapter 14

    Tendinopathy as a Metabolic Signal: Screening Before the Procedure

    Wash Out the Lesion, Don't Jam the Signal | The Pained Brain, Chapter 14

    Tendinopathy as a Metabolic Signal: Screening Before the Procedure

    Recalcitrant tendinopathy is a metabolic signal: an A1c above 5.7 percent, the triglyceride-to-HDL pattern and the metabolic syndrome all track with it, even when body mass index is matched. Screening those numbers and body composition before the procedure sets expectations and puts metabolic work on the same care plan as the tendon.

    Chronic tendinopathy arrives as a musculoskeletal complaint and leaves as a referral. The glycemic, lipid and body composition data that predict how it responds are rarely part of the handoff.

    Recalcitrant tendinopathy usually enters the chart as a musculoskeletal complaint and leaves it as a referral: to physical therapy, to an injection, to a percutaneous tenotomy, occasionally to a stimulator trial. What rarely travels with it is the metabolic context that predicts how the tendon will respond to any of those. The chapter video, Wash Out the Lesion, Don’t Jam the Signal, presents chapter 14 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. The procedure evidence and its grading are in the book companion for chapter 14; the focus here is what a primary care, pain, endocrine or geriatric practice should measure around that decision.

    Is tendinopathy linked to the metabolic syndrome?

    A Danish population cohort followed 5,856 people for three years. A hemoglobin A1c above 5.7 percent was associated with approximately a threefold risk of hospital-treated tendon injury in the lower extremities, and the metabolic syndrome with approximately 2.5 times the risk in upper and lower extremities alike. In a case-control study of 60 patients with midportion Achilles tendon disease against 60 controls matched for age, sex and body mass index, patients had higher triglycerides, lower HDL, a higher triglyceride-to-HDL ratio and higher apolipoprotein B. A pooled analysis of 17 studies and 2,612 participants found triglycerides 0.33 mmol/L and LDL cholesterol 1.00 mmol/L higher in people with tendon pain or altered tendon structure.

    Adiposity adds its own gradient. Across 22 studies and 49,914 participants, obesity carried odds ratios of 3.81 for Achilles tendon disease in class I and 6.56 in class III, and 2.97 for plantar fascia disease; a body mass index above 27 carried an odds ratio of 3.7 for plantar fasciopathy, most strongly outside athletic populations. The evidence tier is observational and largely case-control, with reverse causation possible. The direction is nonetheless consistent, and the BMI-matched lipid finding argues that the signal is metabolic rather than purely mechanical.

    How does a metabolic finding change tendinopathy management?

    Loading is the treatment the rest of the plan exists to enable. In a randomized trial of 204 people with gluteal tendon pain, education plus exercise outperformed corticosteroid injection by 20.4 percent in global success at one year, a number needed to treat of 4.9. Pooled dose data favor added external load over body weight, 1.4 against 0.9 in within-arm effect size, and less-than-daily over daily sessions.

    The terrain changes how far that loading goes. In a retrospective comparison of 28 patients with the metabolic syndrome and 28 matched controls on an identical eccentric program for insertional Achilles tendon disease, the metabolic group reported higher pain throughout follow-up, lower satisfaction and greater analgesic use. After bariatric surgery in 163 patients with plantar fasciitis, a mean excess weight loss of 51.0 percent accompanied symptom resolution in 90 percent, without a way to separate unloading from metabolic change.

    Practically, a documented metabolic phenotype does three things. It sets expectations before a procedure or a rehabilitation block, so that a slow response is interpreted rather than escalated. It puts metabolic work on the same care plan as the tendon work instead of in a separate silo. And it gives the interventionalist and therapist the context their notes usually lack; only 44 percent of published tenotomy studies prescribed structured rehabilitation at all. The social driver is the handoff itself: each specialist in the chain sees the tendon, and nobody is assigned the terrain.

    Which tendinopathy patients should be screened?

    • Tendon pain or plantar fasciopathy that has not settled with an adequate loading program.
    • Lower-extremity tendon disease in a patient with obesity, or with a body mass index above 27 and heel pain.
    • Any patient being referred for a percutaneous tendon procedure or a neuromodulation evaluation for tendon-region pain.
    • Patients previously told they are not diabetic whose last A1c sat in the prediabetic band.
    • A medication history that includes fluoroquinolone exposure, which carried an odds ratio of 3.95 for Achilles tendinitis in pooled studies, documented as a risk factor in the history.

    Practice-level criteria are summarized under selection criteria.

    What Measura measures in this pathway

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service; it does not perform tenotomy, injections or any treatment, and it reports to the ordering physician. The relevant measurements are laboratory panels for the glycemic and lipid picture, and bioimpedance body composition to separate lean from fat mass in patients whose BMI understates or overstates their metabolic risk. Where an older patient with hip or foot tendon pain also reports unsteadiness or a prior fall, vestibular and balance testing belongs in the same visit, and the cognitive assessment and fall prevention workflow keeps that documentation together.

    Standing orders and documentation

    The reproducible version is a standing order that attaches metabolic labs and body composition to any referral for recalcitrant tendinopathy, so the baseline exists before the procedure note does. At an annual wellness visit, the same results support the cardiometabolic documentation that HEDIS and value-based care frameworks already track, as quality documentation rather than as an indication in itself. Repeat measurement during rehabilitation shows whether the terrain is moving alongside the tendon. The related question of what precision a procedure needs is in the diagnostic nerve block referral.

    The limits, stated once

    Percutaneous tenotomy is graded Level 4 by systematic review, with no sham-controlled trial of tissue removal yet, and nerve stimulation has never been tested against a tendon lesion in a randomized trial. The metabolic associations are observational. The practice position is unchanged by either fact: a procedure is a bridge that buys a window for loading, and the metabolic terrain decides whether that window becomes a repair. Measure the terrain first, and keep measuring it. Patients can read the patient version. The joint version of this pattern shows up in hands that bear no weight, laid out in metabolic screening in osteoarthritis.

    Frequently asked questions

    Is tendinopathy associated with insulin resistance?

    The association is consistent across designs. Patients with Achilles tendon disease showed the triglyceride-to-HDL pattern of insulin resistance against BMI-matched controls, and a prospective Danish cohort linked an A1c above 5.7 percent to about a threefold risk of lower-extremity tendon injury. The data are observational, so causation is not established. The wider clinical rationale for cardiometabolic measurement in musculoskeletal patients follows the same reasoning.

    Which laboratory values are most useful in recalcitrant tendinopathy?

    The studied markers are hemoglobin A1c, triglycerides, HDL and LDL cholesterol, and apolipoprotein B, with the triglyceride-to-HDL ratio as a practical summary. The book’s own rehabilitation planning begins with fasting insulin. Uric acid has been linked to Achilles rupture rather than chronic tendon disease. Available panels and ordering are described under laboratory panels.

    Does metabolic status change rehabilitation expectations?

    It appears to. Patients with the metabolic syndrome on an identical eccentric program for insertional Achilles tendon disease had more pain, less satisfaction and more analgesic use than matched controls over follow-up. Documenting that phenotype lets the team read a slow response as expected rather than as treatment failure, and address the terrain in parallel. Outcome tracking is covered under what changes for the patient.

    How can metabolic testing be built into tendon referrals?

    A standing order tied to the referral itself is the most reproducible approach: metabolic labs and body composition drawn when a patient is sent for injection, tenotomy or neuromodulation evaluation. That keeps the decision from depending on the individual clinician and puts the baseline in place before intervention. Templates and scope are outlined in standing orders for screening.

    Where do Measura results go, and who acts on them?

    Results return to the ordering physician, who interprets them in context and decides on management; Measura does not diagnose disease on its own or treat. Findings can be filed as structured data so they remain visible when later procedure and therapy notes arrive. The mechanics are described in getting results into the record.

    How do you heal tendinopathy?

    Loading is the treatment the rest of the plan exists to enable. In a randomized trial of 204 people with gluteal tendon pain, education plus exercise beat corticosteroid injection by 20.4 percent in global success at one year, a number needed to treat of 4.9. Pooled dose data favor added external load over body weight and less-than-daily over daily sessions. The metabolic terrain decides how far that loading goes.

    Add the terrain to the tendon referral

    Learn how the Measura protocol attaches metabolic labs and body composition to musculoskeletal referrals, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Skovgaard, D., Siersma, V. D., Klausen, S. B., Visnes, H., Haukenes, I., Bang, C. W., Bager, P., Grävare Silbernagel, K., Gaida, J., Magnusson, S. P., Kjaer, M., & Couppé, C. (2021). Chronic hyperglycemia, hypercholesterolemia, and metabolic syndrome are associated with risk of tendon injury. Scandinavian Journal of Medicine & Science in Sports, 31(9), 1822–1831. https://doi.org/10.1111/sms.13984
    • Gaida, J. E., Alfredson, L., Kiss, Z. S., Wilson, A. M., Alfredson, H., & Cook, J. L. (2009). Dyslipidemia in Achilles tendinopathy is characteristic of insulin resistance. Medicine and Science in Sports and Exercise, 41(6), 1194–1197. https://doi.org/10.1249/MSS.0b013e31819794c3
    • Tilley, B. J., Cook, J. L., Docking, S. I., & Gaida, J. E. (2015). Is higher serum cholesterol associated with altered tendon structure or tendon pain? A systematic review. British Journal of Sports Medicine, 49(23), 1504–1509. https://doi.org/10.1136/bjsports-2015-095100
    • Macchi, M., Spezia, M., Elli, S., Schiaffini, G., & Chisari, E. (2020). Obesity Increases the Risk of Tendinopathy, Tendon Tear and Rupture, and Postoperative Complications: A Systematic Review of Clinical Studies. Clinical Orthopaedics and Related Research, 478(8), 1839–1847. https://doi.org/10.1097/CORR.0000000000001261
    • van Leeuwen, K. D., Rogers, J., Winzenberg, T., & van Middelkoop, M. (2015). Higher body mass index is associated with plantar fasciopathy/’plantar fasciitis’: systematic review and meta-analysis of various clinical and imaging risk factors. British Journal of Sports Medicine, 50(16), 972–981. https://doi.org/10.1136/bjsports-2015-094695
    • Park, Y. H., Kim, W., Kim, J. Y., Choi, G. W., & Kim, H. J. (2021). Clinical Impact of Metabolic Syndrome on Eccentric Exercises for Chronic Insertional Achilles Tendinopathy. Journal of Foot and Ankle Surgery, 61(4), 726–729. https://doi.org/10.1053/j.jfas.2021.03.020
    • Mellor, R., Bennell, K., Grimaldi, A., Nicolson, P., Kasza, J., Hodges, P., Wajswelner, H., & Vicenzino, B. (2018). Education plus exercise versus corticosteroid injection use versus a wait and see approach on global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised clinical trial. BMJ, 361, k1662. https://doi.org/10.1136/bmj.k1662
    • Pavlova, A. V., Shim, J. S. C., Moss, R., Maclean, C., Brandie, D., Mitchell, L., Greig, L., Parkinson, E., Alexander, L., Tzortziou Brown, V., Morrissey, D., Cooper, K., & Swinton, P. A. (2023). Effect of resistance exercise dose components for tendinopathy management: a systematic review with meta-analysis. British Journal of Sports Medicine, 57(20), 1327–1334. https://doi.org/10.1136/bjsports-2022-105754
    • Buttinger, J. N., Johnson, A. J., Twohey, E. E., Gibson, D. J., Nagelli, C. V., Johnson, S. E., & Romero, J. M. (2026). A systematic review of post-procedural rehabilitation protocols following percutaneous needle tenotomy and ultrasonic debridement for gluteal, proximal hamstring, and patellar tendinopathy. American Journal of Physical Medicine & Rehabilitation. online ahead of print (2026-06-17). https://doi.org/10.1097/PHM.0000000000003031
    • Maag, L., Linder, S., Hackett, L., Mitchkash, M., Farley, T., Lamar, D., Fisher, N., & Burnham, B. (2024). Effectiveness of percutaneous needle tenotomy for tendinopathies: A systematic review. Sports Health, 17(4), 834–842. https://doi.org/10.1177/19417381241275659

    Related reading

  • Dr. Gurpreet Singh Padda presenting the title card Injecting Blindly Is Accepting Failure, The Pained Brain, Chapter 13

    Before the Diagnostic Nerve Block: What the Referring Chart Needs

    Injecting Blindly Is Accepting Failure | The Pained Brain, Chapter 13

    Before the Diagnostic Nerve Block: What the Referring Chart Needs

    A diagnostic nerve block referral should carry a measured baseline, such as bioimpedance body composition rather than body mass index alone, and the result should come back with how the block was done: imaging, volume and sedation. Without that record, an inaccurate block and an accurate negative one look identical in the chart.

    A block result is only as reliable as the address it reached and the patient reporting relief. The referring physician controls neither, but controls what is measured and documented before the referral is written.

    A diagnostic nerve block is a measurement, and like any measurement it carries error that the referring chart rarely sees. The primary care or pain physician who orders the referral does not hold the needle, but does decide what is documented before it, and that record shapes how the result is read afterward. The chapter video, Injecting Blindly Is Accepting Failure, presents chapter 13 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD; the study-level detail, with the limits of each paper, is in the book companion for chapter 13.

    How accurate is a diagnostic nerve block?

    The multispecialty lumbar facet guideline reports that a medial branch block under fluoroscopy misses its target nerve less than 2 percent of the time, while attempts to enter the facet joint itself fail 29 to 38 percent of the time. Selectivity is a separate problem from placement. In the cervical guideline, raising the injectate from a quarter to 0.5 milliliter more than doubled spread beyond the intended level, 16 percent versus 38. Light sedation more than doubled the positive rate at a 50 percent relief threshold and tripled it at 80, which is why that committee recommends performing the block without sedation.

    Then there is the false negative. Intravascular uptake occurs in 4 to 19 percent of lumbar medial branch blocks, and when the anesthetic drains into a vein the generator is declared innocent. An uncontrolled single cervical block carries reported false-positive rates of 36 to 55 percent, and a single sacroiliac injection about 20 percent. Both directions of error land in the referring record as a clean yes or no.

    Why does block selection change ablation results?

    The randomized comparison of zero, one or two blocks before lumbar facet denervation is honest in both directions. Among patients who actually proceeded to denervation, success rose from 33 percent with no block to 64 percent after comparative blocks, although per randomized patient the no-block arm did as well because blocks screen out some eventual responders. The largest negative ablation trial enrolled its sacroiliac arm on a single lenient block that only 24 percent of screened patients failed, so a loose selection step became a population result. The exception also belongs in the note: before cooled genicular ablation, a prognostic block produced 58.6 percent success against 64.0 percent without it.

    The practice position is to block twice, imaged, with an awake patient. For the referring physician, the operational point is simpler. A result labeled non-responder is only interpretable if the chart records how the block was done.

    Why is landmark placement less accurate in patients with obesity?

    Blind placement performs worst in exactly the patients primary care sees most. Palpation of the intercristal line placed the fourth lumbar interspace correctly in 75.3 percent of participants overall and 34 percent of obese participants. In a scoped knee series, landmark accuracy fell at a body mass index of 30 or more. Across 106 consecutive blind shoulder injections, providers could not predict which of their own injections had landed, regardless of experience.

    Two biological drivers compound that. Adiposity alters the anatomy a landmark assumes, and insulin resistance shapes the tissue the procedure is meant to buy time for. The third driver is structural: the referral pathway returns a procedure note to primary care, not a record of guidance, contrast or sedation, so an inaccurate block and an accurate negative one look identical in the chart. Documenting bioimpedance body composition rather than body mass index alone gives the receiving interventionalist a better description of the patient, and gives the referring physician a baseline for the rehabilitation phase that follows any successful block.

    What Measura adds before the referral

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service. It performs no injections, no imaging and no treatment, and its findings return to the ordering physician. Its place in this pathway is the terrain the procedure lands in, which the book treats as the half of the plan that decides whether the bridge leads anywhere.

    • Metabolic status. Laboratory panels document the insulin-resistance picture that a pain referral almost never includes.
    • Body composition. Fat and lean compartments, measured rather than inferred from weight and height.
    • Small-fiber function. When the complaint is distal burning rather than axial pain, sudomotor testing documents sweat-gland function of the small nerve fibers in the hands and feet, a question no facet block is designed to answer.
    • Cognition. A diagnostic block’s endpoint is patient-reported relief, recorded by an awake patient. A cognitive assessment baseline is already part of annual wellness documentation, and pairing it with fall-prevention screening keeps both in the same visit.

    Standing orders, documentation and quality reporting

    None of this requires a new pathway, only a reproducible one. A standing order can attach metabolic, body composition and, where indicated, small-fiber testing to referrals for interventional pain evaluation, so the decision does not depend on who saw the patient that day. Results filed as discrete data in the record stay visible when the procedure note comes back. The same findings support cardiometabolic documentation that MIPS and quality reporting already ask practices to capture, as documentation rather than as a reason to test.

    A useful addition to the referral letter costs one sentence: request image guidance with contrast, and an awake patient for any diagnostic block, and ask that the procedure note state both. That sentence turns an unreadable negative into data.

    What the evidence does not settle

    Accuracy and outcome are separate claims. Across 19 shoulder trials, the Cochrane reviewers found ultrasound-guided steroid injection better than unguided by only 0.5 points on a ten-point scale, because corticosteroid diffuses and works from a near miss. That is exactly why steroid trials are the wrong test for a diagnostic block, whose value is the question rather than the drug. Novices needed about 28 supervised attempts to reach competence in ultrasound needle visualization on cadavers. The position stands: image every diagnostic block, keep the patient awake, and treat the procedure as a bridge whose far bank is the metabolic and functional work measured before and after it. Patients can read the patient-facing explanation.

    Frequently asked questions

    Should patients be sedated for a diagnostic medial branch block?

    The cervical consensus guideline recommends against it. Light sedation more than doubled the positive rate at a 50 percent relief threshold and tripled it at 80, which inflates false positives and sends the wrong patients to ablation. Patients also typically go home within two to four hours of an unsedated block. The broader clinical rationale for measuring before intervening follows the same logic.

    How many diagnostic blocks should precede radiofrequency ablation?

    The guidelines do not agree. For the neck, a single block at 50 percent relief is accepted to preserve access, while comparative blocks raised success among patients who reached lumbar denervation from 33 to 64 percent. Before sacroiliac fusion the guideline reports two blocks with at least 75 percent relief. The prevalence of each pain generator is its own topic, covered in proving the pain generator.

    Which referred patients should have metabolic and body composition testing?

    Patients referred for interventional evaluation who have obesity, known or suspected insulin resistance, prediabetes, or a history of procedures that did not help are reasonable candidates, because those findings change both the interpretation of the procedure and the rehabilitation plan. Distal burning pain adds small-fiber testing. Practice-level criteria are summarized in selection criteria.

    How does this fit into an annual wellness visit?

    The annual wellness visit already documents cognitive status and fall risk, and it is the natural point to attach metabolic and body composition measurement for a patient with chronic pain. Doing it there means the baseline exists before any referral is written, rather than being reconstructed afterward. Workflow details are in annual wellness visit integration.

    Does Measura perform or interpret interventional procedures?

    No. Measura measures vascular, autonomic, nerve, metabolic, body composition and cognitive function and reports to the ordering physician. Diagnostic blocks, imaging and ablation remain with the interventional specialist. The testing supplies the context a procedure note lacks, and the ways different specialties use it are described in specialty applications.

    What happens next if a diagnostic nerve block does not work?

    First check how the block was done. A negative result is only interpretable if the procedure note records image guidance, contrast, injectate volume and whether the patient was sedated. Intravascular uptake occurs in 4 to 19 percent of lumbar medial branch blocks and can make a true pain generator look innocent. Without that record, an inaccurate block and an accurate negative one look identical in the chart.

    Can a diagnostic nerve block give a false result?

    Yes, in both directions. Light sedation more than doubled the positive rate at a 50 percent relief threshold, and an uncontrolled single cervical block carries reported false-positive rates of 36 to 55 percent. Anesthetic that drains into a vein produces false negatives, and a larger injectate volume spreads beyond the intended level. That is why the practice position is two imaged blocks with an awake patient.

    Build measurement into the referral pathway

    See how the Measura protocol attaches metabolic, body composition and nerve-function testing to interventional referrals, with results returned to the ordering physician.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Cohen, S. P., Bhaskar, A., Bhatia, A., Buvanendran, A., Deer, T., Garg, S., Hooten, W. M., Hurley, R. W., Kennedy, D. J., McLean, B. C., Moon, J. Y., Narouze, S., Pangarkar, S., Provenzano, D. A., Rauck, R., Sitzman, B. T., Smuck, M., van Zundert, J., Vorenkamp, K., … Zhao, Z. (2020). Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group. Regional Anesthesia and Pain Medicine, 45(6), 424–467. https://doi.org/10.1136/rapm-2019-101243
    • Hurley, R. W., Adams, M. C. B., Barad, M., Bhaskar, A., Bhatia, A., Chadwick, A., Deer, T. R., Hah, J., Hooten, W. M., Kissoon, N. R., Lee, D. W., Mccormick, Z., Moon, J. Y., Narouze, S., Provenzano, D. A., Schneider, B. J., van Eerd, M., Van Zundert, J., Wallace, M. S., … Cohen, S. P. (2022). Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group. Regional Anesthesia and Pain Medicine, 47(1), 3–59. https://doi.org/10.1136/rapm-2021-103031
    • Cohen, S. P., Williams, K. A., Kurihara, C., Nguyen, C., Shields, C., Kim, P., Griffith, S. R., Larkin, T. M., Crooks, M., Williams, N., Morlando, B., & Strassels, S. A. (2010). Multicenter, randomized, comparative cost-effectiveness study comparing 0, 1, and 2 diagnostic medial branch (facet joint nerve) block treatment paradigms before lumbar facet radiofrequency denervation. Anesthesiology, 113(2), 395–405. https://doi.org/10.1097/ALN.0b013e3181e33ae5
    • Juch, J. N. S., Maas, E. T., Ostelo, R. W. J. G., Groeneweg, J. G., Kallewaard, J. W., Koes, B. W., Verhagen, A. P., van Dongen, J. M., Huygen, F. J. P. M., & van Tulder, M. W. (2017). Effect of Radiofrequency Denervation on Pain Intensity Among Patients With Chronic Low Back Pain: The Mint Randomized Clinical Trials. JAMA, 318(1), 68–81. https://doi.org/10.1001/jama.2017.7918
    • McCormick, Z. L., Hurley, R. W., Anitescu, M., Bhaskar, A., Bhatia, A., Cassidy, R. C., Chen, A. S., Dawson, T. C., De Andrés Ares, J., de Campos, J. L., Hayek, S. M., Hernández-Porras, B. C., Kissoon, N. R., Kohan, L. R., Elgueta Le Beuffe, M. F., Moon, J. Y., Provenzano, D. A., Reece, D. E., Schuster, N. M., … Cohen, S. P. (2025). Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group. Pain Medicine, 26(12), 817–917. https://doi.org/10.1093/pm/pnaf129
    • McCormick, Z. L., Reddy, R., Korn, M., Dayanim, D., Syed, R. H., Bhave, M., Zhukalin, M., Choxi, S., Ebrahimi, A., Kendall, M. C., McCarthy, R. J., Khan, D., Nagpal, G., Bouffard, K., & Walega, D. R. (2018). A Prospective Randomized Trial of Prognostic Genicular Nerve Blocks to Determine the Predictive Value for the Outcome of Cooled Radiofrequency Ablation for Chronic Knee Pain Due to Osteoarthritis. Pain Medicine, 19(8), 1628–1638. https://doi.org/10.1093/pm/pnx286
    • Malik, M., & Ismail, S. (2019). Accuracy of Tuffier’s Line Identification by Palpation Method: Cross-Sectional Comparative Study Among Obese, Pregnant and Control Groups. Turkish Journal of Anaesthesiology and Reanimation, 48(2), 108–114. https://doi.org/10.5152/TJAR.2019.82346
    • Zadro, J., Rischin, A., Johnston, R. V., & Buchbinder, R. (2021). Image-guided glucocorticoid injection versus injection without image guidance for shoulder pain. Cochrane Database of Systematic Reviews, 8(8), CD009147. https://doi.org/10.1002/14651858.CD009147.pub3

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the Chapter 12 title card of The Pained Brain

    Epidural Steroid Injection Overuse: Measuring the Terrain First

    The System Profits From Your Pain | The Pained Brain, Chapter 12

    Epidural Steroid Injection Overuse: Measuring the Terrain First

    Epidural steroid injection overuse is a pattern of repeat procedures with no measured reason or result behind them. The correction is a documented metabolic, cognitive and balance baseline taken before the next procedure and taken again after it.

    Utilization data record how often the needle is used and nothing about the patient it was used on. A baseline measured before the next procedure is the outcome field the claims never had.

    Epidural steroid injection overuse is almost never visible in one chart. It appears in aggregate: in traditional Medicare the transforaminal epidural rose 579 percent between 2000 and 2010, and in commercial claims patients averaged 4.46 spinal procedures in the twelve months after their first. Chapter 12 of The Pained Brain, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, defends the procedure as a bridge and rejects it as a destination. For a practice, the variable that separates the two is measurable: whether anything about the patient’s terrain was documented before the next procedure and documented again after it.

    Why can’t claims data show epidural steroid injection overuse?

    The utilization literature shares a limitation that matters more than its magnitude: none of it carries an indication or an outcome. In a cohort of 196,332 commercially insured patients, the busiest tenth of providers performed 36.6 percent of spinal procedures, nine times the lowest tenth. After a first lumbar medial branch ablation in 44,936 patients, repeats accumulated to 45.7 percent by seven years. Across 4,108,121 patients with a lumbar degenerative diagnosis, the annual injection rate held near 10 percent, and states that injected more also operated more. Since 2019 the direction has reversed, with interventional techniques down 16.8 percent in traditional Medicare through 2024.

    Both trends are uninterpretable at the patient level. A repeat ablation after genuine relief can be guideline-consistent, and claims cannot tell a planned repeat from a failure; a decline cannot tell better selection from reduced access. The same fix answers both: record a measured state of the patient that can be compared over time.

    What drives repeat spinal procedures?

    In a study of 31 physician organizations affiliated with 22 health systems, volume formed the base incentive for 93.3 percent of specialist incentive plans and for 83.9 percent in primary care, with quality metrics carrying a minor share of the weighting. Practices tend to cite a different driver. Surveyed, 2,106 physicians estimated a median 20.6 percent of care is unnecessary and named malpractice fear most often. Yet when 36 hospitalists rated 4,215 of their own orders, 28 percent carried some defensive motive, and those claiming the most defensive orders did not order more than their peers. Habit, referral patterns and training carry part of the pattern too, which is exactly why structure, not exhortation, has to change the default.

    Epidural steroid injection overuse: what the repeat-procedure chart omits

    The composite patient in the chapter arrives for his ninth epidural with imaging, a nerve study and a surgical opinion on file, and no fasting insulin, diet history or sleep history. The medication burden that accompanies that pattern is well described. Excessive polypharmacy, ten or more agents, reached 25.9 percent in a Quebec chronic pain cohort. Of 20,422 discharges of older polypharmacy inpatients, an opioid combined with a hypnotic appeared in 24.5 percent of those with chronic noncancer pain. In nursing homes, roughly one resident in twenty started on a gabapentinoid had a loop diuretic added within three months.

    The two biological drivers the procedure pathway leaves unmeasured are metaflammation with insulin resistance and the iatrogenic load of the regimen itself. Neither appears in a utilization count, and both can be measured in an ordinary clinic.

    A measured baseline before the next procedure

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service; it measures, does not treat, and returns results to the ordering physician. For a patient on a repeat-procedure pathway, a documented baseline might include:

    Standing orders make the baseline reproducible instead of dependent on who staffs the clinic that day. The annual wellness visit is a natural anchor, and structured results feed the documentation that MIPS and HEDIS reporting rely on.

    How does remeasurement show whether a plan worked?

    The clearest demonstration that terrain moves comes from outside pain. The DiRECT trial began from the premise that type 2 diabetes requires lifelong treatment and randomized primary care practices to a structured weight-management program. Remission ran 46 against 4 percent at one year and 36 against 3 at two, with antidiabetic drugs still prescribed in 40 against 84 percent. The response was graded by weight lost: 57 percent remission at 10 to 15 kilograms and 86 percent at 15 or more. That gradient is what a practice can only see if weight, composition and metabolic markers were measured at the start.

    The pain data are smaller and honest. Multidisciplinary rehabilitation improves pain by about half a point on a ten-point scale over usual care. Its larger contribution is dependency: in 1,457 patients in a three-week program, 86.74 percent of opioid users were weaned with no difference in improvement by admission dose, though 30.70 percent resumed within a year. Across 86 samples and 15,616 patients, self-efficacy predicted impairment, distress and pain prospectively, which argues for showing patients their own measured change.

    Why the process reforms missed

    Choosing Wisely was followed by a 4 percent relative reduction in low-value back imaging, and a value-based primary care program left back imaging at 13.8 percent in both arms. Both targeted the order, not the patient. Continuity is the counterexample: annual physician face time per person in the United States is 60.4 minutes, while 18 of 22 studies linked greater continuity with lower mortality, and among 4,552,978 Norwegians more than fifteen years with one physician carried an odds ratio for death of 0.75. Decision aids made a values-matched choice 1.75 times as likely. Measurement, continuity and a shared decision are one workflow. The preceding topic in the series is screening for cluster headache, the next is image guidance, and every study cited is in the Chapter 12 technical companion.

    Frequently asked questions

    Which patients on repeat procedures warrant a metabolic baseline?

    Candidates include patients returning for the same procedure at the same level, patients on five or more medications, and those whose regimen combines sedating agents. Your practice’s own criteria should define the trigger so the decision does not depend on who sees the patient. A baseline is documentation of state, not an indication for or against a procedure. The framework is laid out in selection criteria.

    How does a baseline fit the annual wellness visit?

    The annual wellness visit already asks for a structured review of function, cognition and fall risk, which makes it a practical point to schedule laboratory panels, body composition and cognitive and balance measures. Results arrive in time for the medication review and procedure planning that follow. The workflow is described on the annual wellness visit integration page.

    Does Measura testing determine whether a procedure is indicated?

    No. Indication remains a clinical judgment based on history, examination and imaging. Measura results describe metabolic, autonomic, body-composition, cognitive and balance status, which gives the treating physician a measured starting point and a way to show whether the time a procedure buys is changing anything. Guidance on reading those results is on interpreting the report.

    Why pair cognitive and balance testing with medication review?

    Regimens in chronic pain frequently combine opioids with hypnotics or gabapentinoids, and one in four older inpatients with chronic noncancer pain in one register was on an opioid plus a hypnotic. A cognitive and balance baseline gives the prescriber an objective reference before and after regimen changes and connects the review to fall prevention. See cognitive assessment and fall prevention.

    What should be remeasured, and when?

    Remeasure whatever the plan claims it will change, on a schedule set by the treating physician: metabolic markers and body composition when weight, food or activity are the target, cognitive and balance measures after regimen changes. The comparison is what converts a repeat visit into a documented outcome. Between-visit tracking is discussed on chronic care and between-visit monitoring.

    Are epidural steroid injections overused?

    Overuse shows up in aggregate rather than in a single chart. Transforaminal epidurals in traditional Medicare rose 579 percent between 2000 and 2010, commercially insured patients averaged 4.46 spinal procedures in the year after their first, and the busiest tenth of providers performed 36.6 percent of spinal procedures. None of those counts records an indication or an outcome, which is why a measured baseline matters.

    Is an epidural steroid injection a long-term solution?

    Chapter 12 of The Pained Brain defends the epidural as a bridge and rejects it as a destination. A procedure buys time, and the question is whether that time changes anything. The variable that separates a bridge from a repeat pathway is measurable: whether the patient’s metabolic, cognitive and balance baseline was documented before the next procedure and taken again after it.

    Learn how the protocol fits your practice

    See how Measura baselines are ordered through standing orders, performed on site and returned to the chart for procedure and medication planning.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Abbott, Z. I., Nair, K. V., Allen, R. R., & Akuthota, V. R. (2012). Utilization characteristics of spinal interventions. The Spine Journal, 12(1), 35–43. https://doi.org/10.1016/j.spinee.2011.10.005
    • Starr, J. B., Gold, L. S., McCormick, Z., Suri, P., & Friedly, J. (2019). Repeat procedures and prescription opioid use after lumbar medial branch nerve radiofrequency ablation in commercially insured patients. The Spine Journal, 20(3), 344–351. https://doi.org/10.1016/j.spinee.2019.10.005
    • Reid, R. O., Tom, A. K., Ross, R. M., Duffy, E. L., & Damberg, C. L. (2022). Physician Compensation Arrangements and Financial Performance Incentives in US Health Systems. JAMA Health Forum, 3(1), e214634. https://doi.org/10.1001/jamahealthforum.2021.4634
    • Rothberg, M. B., Class, J., Bishop, T. F., Friderici, J., Kleppel, R., & Lindenauer, P. K. (2014). The cost of defensive medicine on 3 hospital medicine services. JAMA Internal Medicine, 174(11), 1867–1868. https://doi.org/10.1001/jamainternmed.2014.4649
    • Zahlan, G.; De Clifford-Faugère, G.; Nguena Nguefack, H. L.; Guénette, L.; Pagé, M. G.; Blais, L.; Lacasse, A. (2023). Polypharmacy and Excessive Polypharmacy Among Persons Living with Chronic Pain: A Cross-Sectional Study on the Prevalence and Associated Factors. J Pain Res, 16, 3085–3100. https://doi.org/10.2147/JPR.S411451
    • Lean, M. E.; Leslie, W. S.; Barnes, A. C.; Brosnahan, N.; Thom, G.; McCombie, L.; Peters, C.; Zhyzhneuskaya, S.; Al-Mrabeh, A.; Hollingsworth, K. G.; Rodrigues, A. M.; Rehackova, L.; Adamson, A. J.; Sniehotta, F. F.; Mathers, J. C.; Ross, H. M.; McIlvenna, Y.; Stefanetti, R.; Trenell, M.; … Taylor, R. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 391(10120), 541–551. https://doi.org/10.1016/S0140-6736(17)33102-1
    • Huffman, K. L.; Rush, T. E.; Fan, Y.; Sweis, G. W.; Vij, B.; Covington, E. C.; Scheman, J.; Mathews, M. (2017). Sustained improvements in pain, mood, function and opioid use post interdisciplinary pain rehabilitation in patients weaned from high and low dose chronic opioid therapy. Pain, 158(7), 1380–1394. https://doi.org/10.1097/j.pain.0000000000000907
    • Jackson, T., Wang, Y., Wang, Y., & Fan, H. (2014). Self-efficacy and chronic pain outcomes: a meta-analytic review. The Journal of Pain, 15(8), 800–814. https://doi.org/10.1016/j.jpain.2014.05.002
    • Sandvik, H., Hetlevik, Ø., Blinkenberg, J., & Hunskaar, S. (2022). Continuity in general practice as predictor of mortality, acute hospitalisation, and use of out-of-hours care: a registry-based observational study in Norway. British Journal of General Practice, 72(715), e84–e90. https://doi.org/10.3399/BJGP.2021.0340
    • Stacey, D., Lewis, K. B., Smith, M., Carley, M., Volk, R., Douglas, E. E., Pacheco-Brousseau, L., Finderup, J., Gunderson, J., Barry, M. J., Bennett, C. L., Bravo, P., Steffensen, K., Gogovor, A., Graham, I. D., Kelly, S. E., Légaré, F., Sondergaard, H., Thomson, R., … Trevena, L. (2024). Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews, 1(1), CD001431. https://doi.org/10.1002/14651858.CD001431.pub6

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 11 title card of The Pained Brain reading The Most Painful Headache Requires Minutes, Not Weeks

    Screening for Cluster Headache in Primary Care: A Three-Item Workflow

    The Most Painful Headache Requires Minutes, Not Weeks | The Pained Brain, Chapter 11

    Screening for Cluster Headache in Primary Care: A Three-Item Workflow

    Screen for cluster headache in primary care with the Erwin Test, a validated three-item decision tree on pain intensity, attack duration and same-side autonomic features, with 84 percent sensitivity and 89 percent specificity. Trigger it for recurrent unilateral head or face pain, let clinical staff give it by standing order, and record the answers in a structured field.

    The median patient reaches a correct cluster headache diagnosis after a decade of wrong ones. The tool that shortens that interval takes three questions and a structured field in the record.

    Screening for cluster headache in primary care is a workflow problem before it is a pharmacology problem. The pooled interval from first attack to correct diagnosis is 10.43 years across 22 studies, only 21 percent of 1,134 American survey respondents were identified correctly at initial presentation, and the instrument that would close much of that gap already exists. Chapter 11 of The Pained Brain, the video above, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, treats the disorder as time-critical. For a practice the operational questions are narrower: where a validated screen sits in intake, and what a positive result sets in motion.

    Why does cluster headache take so long to diagnose?

    The 10.43-year mean needs a caveat that sharpens it. It is inflated by older cohorts, and delay has fallen by decade of onset in British and Danish series. First-contact accuracy has not kept pace. In 144 Italian and Eastern European episodic patients, 77 percent were misdiagnosed at first consultation with 2.27 diagnoses each, and 93 percent underwent instrumental or laboratory testing. In a Portuguese series of 64, before the correct label 17.2 percent had received opioids and 14.1 percent dental procedures. In an American chart-validated cohort of 75, mean delay was 12.7 years, and the excess dental, TMJ and septal diagnoses were judged very likely to be misdiagnoses rather than comorbidity.

    Three drivers sustain the pattern. Attack timing is hypothalamic, and pain is delivered through the trigeminal-parasympathetic reflex, so the event resolves before examination and is silent on imaging. The third is organizational: among 218 family and emergency physicians, 15 percent rated themselves sufficiently knowledgeable, nearly half did not know autonomic features are mandatory for diagnosis, 72.5 percent of family physicians send an acute attack to the emergency department, and 92.9 percent of emergency respondents manage these patients in the lowest-acuity zone.

    How accurate is screening for cluster headache in primary care?

    The Erwin Test for Cluster Headache is a three-item decision tree on intensity, duration and autonomic features, validated in 319 participants including 109 with cluster headache. Reported sensitivity was 84 percent, specificity 89 percent, positive predictive value 76 percent and negative predictive value 93 percent. The design limits interpretation: single-center validation with enriched recruitment of trigeminal autonomic cephalalgia means positive predictive value in an unselected primary-care panel will run lower, and no study has yet shown the screen shortens delay. Its strengths are the negative predictive value and its brevity.

    Operationally it behaves like any validated instrument: a trigger, a script, a discrete result. A defensible trigger is recurrent unilateral head or face pain, including patients returned from dental or sinus evaluation without a cause. Written as a standing order, it can be administered by clinical staff before the physician enters, and a structured field makes the answer retrievable at the next visit instead of reconstructed from unstructured notes; see getting results into the record.

    Can cluster headache be mistaken for migraine?

    Migraine-like features are common in cluster headache and should not be used to exclude it. In 1,604 questionnaire respondents meeting criteria, 50.1 percent had photophobia or phonophobia, 31.4 percent pain aggravated by activity and 27.5 percent nausea or vomiting, while 99.0 percent had at least one cranial autonomic feature and 96.6 percent restlessness. The authors concluded that prototypical migrainous features do not separate the two disorders.

    Sex compounds the error. In a Swedish biobank of 874 re-verified patients, self-reported migraine was 29.4 percent in women against 12.5 percent in men. In a Chinese registry of 1,206, conjunctival injection was less frequent in women, 38.52 against 56.03 percent, while restlessness was identical. The woman in the exam room is more likely to present as migraine and less likely to show the red eye. Age matters as well: onset before 20 carried a mean 13.8-year delay in 400 Danish patients against 2.1 years after 40, and in the international sample 27.5 percent reported onset before 18, of whom only 15.2 percent were diagnosed before 18. Adolescent visits belong in the screening population.

    What changes after a cluster headache diagnosis?

    The argument for screening rests on what follows a correct label. The American Headache Society lists subcutaneous sumatriptan, zolmitriptan nasal spray and high-flow oxygen as Level A acute treatments and suboccipital steroid injection as the only Level A preventive; opioids are absent, partly because they were never trialed. Practice diverges sharply. Among 7,589 newly diagnosed commercially insured patients, the leading prescription class over the next twelve months was opioids, at 41 percent, and oxygen was claimed by 16.2 percent within seven days of diagnosis. Patients rated opioids completely or very effective in 6 percent against 54 percent for oxygen. Access is the other constraint: of 566 patients who eventually obtained oxygen, 13 percent waited two to five years, and the mean commercial wait for a new neurology visit is 49.7 days. A documented positive screen lets the plan begin during the bout rather than after it.

    Documentation after a positive result

    • The three screen answers, dated, in a discrete field
    • Episodic or chronic classification, because response splits: galcanezumab reduced weekly attacks in episodic disease and missed its primary endpoint in chronic disease, and non-invasive vagus nerve stimulation separated the same way in two sham-controlled trials
    • Prior diagnoses and procedures, dental and sinus interventions included
    • For patients on verapamil, the electrocardiogram schedule: in an audit, 19 percent of 108 patients with tracings on file had an arrhythmia, and 41 percent of 217 treated patients had no tracing at all
    • Refractory status against the consensus definition of at least three severe attacks weekly despite three adequate preventive trials

    Where Measura fits, and where it does not

    Measura [Cardiometabolic and Autonomic Health Analysis] does not diagnose primary headache disorders, and nothing in its library substitutes for the screen or the criteria. It also does not perform the electrocardiogram that verapamil monitoring calls for; that rhythm check remains with the prescriber. Cardiac autonomic reflex tests and heart rate variability quantify systemic autonomic regulation of the heart, a different physiological question from the cranial trigeminal-parasympathetic reflex, and a result should not be read as evidence for or against cluster headache. These measurements belong to the rest of the patient, when your own selection criteria call for an autonomic or cardiometabolic baseline. The circadian physiology behind attack timing is covered in the clock and pain, and the incentive structure that keeps fast, low-intensity care in the slow lane is taken up in the repeat-procedure pathway. Every study cited here, with its limits, is in the Chapter 11 technical companion.

    Frequently asked questions

    What is the Erwin Test for Cluster Headache?

    It is a three-item decision tree covering headache intensity, attack duration and cranial autonomic features. In its validation study of 319 participants it showed 84 percent sensitivity and 89 percent specificity, with a negative predictive value of 93 percent. Recruitment was enriched, so expect lower positive predictive value in general practice. Building it into intake works best when the trigger and result field are fixed; see making screening reproducible.

    Which patients should be screened?

    A practical trigger is recurrent, strictly unilateral head or face pain, particularly in patients carrying a migraine, sinus or dental explanation that has not held up. Adolescents belong in scope, since 27.5 percent of one international sample reported onset before 18 and few were diagnosed then. Women presenting with nausea and light sensitivity deserve the questions rather than a default migraine label. More on applying criteria by specialty is in specialty applications.

    Do nausea and light sensitivity exclude cluster headache?

    No. In 1,604 respondents meeting criteria, half reported photophobia or phonophobia and more than a quarter nausea or vomiting, while nearly all had at least one cranial autonomic feature and most were restless. The authors concluded that migrainous features do not differentiate the disorders. Restlessness during the attack and ipsilateral autonomic signs are the discriminating findings. Common workflow questions are collected in the physician questions page.

    Can autonomic testing confirm or exclude cluster headache?

    No. Autonomic nervous system testing, heart rate variability and cardiac autonomic reflex tests measure systemic autonomic regulation of the heart and circulation. Cluster headache is a clinical diagnosis based on attack pattern and cranial autonomic features, and a normal or abnormal systemic result does not change that. Order autonomic testing when your criteria call for it on its own merits. Details are on the autonomic nervous system testing page.

    How should a positive screen be documented?

    Record the three answers with a date in a discrete field, the episodic or chronic classification, prior diagnoses and procedures, and the monitoring plan for any preventive that needs an electrocardiogram. Structured entries keep the finding visible at the next encounter and support the same documentation discipline used for quality reporting. The MIPS and quality reporting page describes how structured results are handled.

    How does a doctor diagnose cluster headaches?

    Cluster headache is a clinical diagnosis built on the attack pattern: severe one-sided head or face pain, how long each attack lasts, restlessness during the attack and same-side autonomic features such as a red eye. Imaging stays silent because the attack is over before the exam. In primary care, the three-item Erwin Test gives clinical staff a validated way to ask those questions and record the answers in a structured field.

    What treatments are recommended for cluster headache?

    The American Headache Society lists subcutaneous sumatriptan, zolmitriptan nasal spray and high-flow oxygen as Level A acute treatments, and suboccipital steroid injection as the only Level A preventive. Opioids are not on the list. Practice runs the other way: opioids were the leading prescription class after diagnosis, while patients rated oxygen completely or very effective 54 percent of the time and opioids 6 percent.

    See how the protocol fits a practice

    Learn how Measura testing is ordered, performed and returned to the chart when your selection criteria call for an autonomic or cardiometabolic baseline.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Van Obberghen, E. K., Fabre, R., & Lanteri-Minet, M. (2025). Cluster headache diagnostic delay and its predictors: a systematic review with a meta-analysis. The Journal of Headache and Pain, 26(1), 71. https://doi.org/10.1186/s10194-025-02001-7
    • Parakramaweera, R., Evans, R. W., Schor, L. I., Pearson, S. M., Martinez, R., Cammarata, J. S., Amin, A. J., Yoo, S. H., Zhang, W., Yan, Y., & Burish, M. J. (2021). A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache. Cephalalgia, 41(13), 1298–1309. https://doi.org/10.1177/03331024211018138
    • Schor, L. I., Pearson, S. M., Shapiro, R. E., Zhang, W., Miao, H., & Burish, M. J. (2021). Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire. Headache, 61(10), 1511–1520. https://doi.org/10.1111/head.14237
    • Hasirci Bayir, B. R., Nazli, E., & Ulutas, C. (2025). Cluster Headache Management: Evaluating Diagnostic and Treatment Approaches Among Family and Emergency Medicine Physicians. Medicina (Kaunas, Lithuania), 61(3), 437. https://doi.org/10.3390/medicina61030437
    • Joshi, S., Rizzoli, P., & Loder, E. (2017). The comorbidity burden of patients with cluster headache: a population-based study. The Journal of Headache and Pain, 18(1), 76. https://doi.org/10.1186/s10194-017-0785-3
    • Silva, L., Millner, T., Cabral, M., Costa, A., Almeida, P., Barreto, B., Pinto, M., Dias, R., Moreira, S., Bonifácio, G. V., Pinto, S. M., Castro, R., Alves, I., Rocha, A. L., Varanda, S., Costa, A., & Andrade, C. (2026). Delayed diagnosis of cluster headache in Portugal. Arquivos de Neuro-Psiquiatria, 84(9), 1–6. https://doi.org/10.1055/s-0046-1827040
    • Robbins, M. S., Starling, A. J., Pringsheim, T. M., Becker, W. J., & Schwedt, T. J. (2016). Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache, 56(7), 1093–1106. https://doi.org/10.1111/head.12866
    • Choong, C. K., Ford, J. H., Nyhuis, A. W., Joshi, S. G., Robinson, R. L., Aurora, S. K., & Martinez, J. M. (2017). Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data. Headache, 57(9), 1359–1374. https://doi.org/10.1111/head.13127
    • Cohen, A. S., Matharu, M. S., & Goadsby, P. J. (2007). Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology, 69(7), 668–675. https://doi.org/10.1212/01.wnl.0000267319.18123.d3
    • Fourier, C., Ran, C., Steinberg, A., Sjöstrand, C., Waldenlind, E., & Belin, A. C. (2022). Sex Differences in Clinical Features, Treatment, and Lifestyle Factors in Patients With Cluster Headache. Neurology, 100(12), e1207–e1220. https://doi.org/10.1212/WNL.0000000000201688

    Related reading

  • Title card for The ER Will Tell You You're Not Dying. That Is Not a Diagnosis, The Pained Brain Chapter 10, with Dr. Padda presenting

    Low Back Pain Emergency Department Visits: The Primary Care Follow-Up

    The ER Will Tell You You're Not Dying. That Is Not a Diagnosis | The Pained Brain, Chapter 10

    Low Back Pain Emergency Department Visits: The Primary Care Follow-Up

    Primary care follow-up after a low back pain emergency department visit should prioritize patients whose pain persists at one week, repeat presenters, patients discharged with an opioid and patients less likely to have received analgesia. The terrain primary care can measure without a procedure is fasting insulin with glucose and HbA1c, plus body composition.

    The emergency department excludes the catastrophe and discharges everyone else with a location code. The follow-up visit in primary care is where mechanism and terrain can finally be documented.

    Low back pain emergency department visits numbered 52.8 million in the United States between 2016 and 2022, roughly one visit in twenty, with a mean presenting pain score of 7.2. The encounter is engineered to exclude the minority with pathology requiring urgent treatment, and it does so competently. It is not engineered to identify mechanism or terrain, so the patient reaches primary care still carrying both questions.

    Chapter 10 of The Pained Brain, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, makes the structural case in the video above. For the practice receiving the discharge summary, the useful questions are operational: which patients need more than a phone call, what to measure, and how to make it reproducible.

    What does the ER do for lower back pain, and what does it leave out?

    Emergency back-pain care is image-heavy and cause-light. A meta-analysis of 45 studies found imaging in 35.6 percent of emergency low back pain consultations versus 24.8 percent in primary care, with complex imaging climbing despite guideline campaigns. The two most frequent discharge codes are low back pain and dorsalgia, both anatomic descriptors. On vignettes written without red flags, 263 Swiss emergency physicians said they would recommend activity restriction in 72 and 67 percent of the two cases, against guideline advice.

    None of this is a criticism of emergency medicine. The same literature shows emergency physicians rating their own pain care worse than any other specialty surveyed, with an odds ratio of 53 against pain medicine, and 96 percent of responding Canadian emergency physicians reporting no effective chronic-pain pathway from their department. The encounter lacks time and a destination. Metabolic markers are absent for the same reason: fasting insulin is not on an emergency order set for back pain, because it cannot change the disposition decision.

    Which patients need follow-up after a low back pain emergency department visit?

    • Pain persisting at one week. Among 354 patients from two analgesic trials, pain at the one-week call carried an odds ratio of 2.42 for functional impairment and 3.83 for moderate or severe pain at three months, while a psychosocial risk score added no independent prediction.
    • Repeat presenters. In one department’s back-pain sample, 59.2 percent had presented for the same problem before. At a Canadian center, 38 percent of patients making twelve or more visits a year presented with chronic pain.
    • Patients discharged with an opioid. One-year return for the same complaint ran 68 versus 55 percent, confounded by indication. Duration of the first episode tracks persistence: among 1,294,247 opioid-naive adults, 6.0 percent were still taking opioids at a year overall and 29.9 percent when the first episode lasted 31 days or more. Stewardship here means a documented duration and a review date, not abstinence.
    • Patients less likely to have received analgesia. Pooled data show lower odds of any analgesic for Black patients (0.80) and older patients (0.74).

    A general framework for prioritization sits under selection criteria.

    The three questions, and the one primary care can measure

    Dr. Padda frames persistent pain around structure, mechanism and terrain. Structure requires controlled image-guided blocks: six-month success after lumbar medial branch radiofrequency neurotomy was 26 percent when selection rested on a single block and 56 percent after two blocks with complete relief. That is a pain-medicine referral, and the rigor of the diagnostic step determines the downstream result.

    Terrain is what a primary care office can quantify in the follow-up window without a procedure. Measura [Cardiometabolic and Autonomic Health Analysis] performs the measurements and reports them; interpretation and management stay with the ordering physician.

    • Laboratory panels that include fasting insulin with glucose and HbA1c, capturing compensated insulin resistance that a normal glucose conceals.
    • Bioimpedance body composition to separate fat and lean compartments, since BMI alone does not characterize the metabolic load.
    • For older patients, a documented cognitive assessment baseline and fall-risk review belong in the same episode, filed where the next clinician will find them.

    The less obvious point concerns what the system chose to measure. Across 45 studies in the meta-analysis of interventions to reduce emergency opioid prescribing, prescribing fell by 22.61 percent, yet the authors reported insufficient data on pain relief. The field measured the prescription and not the patient. Primary care is positioned to measure the patient.

    What improves outcomes after an emergency visit for back pain?

    Timing matters. In 265 patients receiving physical therapy after an emergency back-pain visit, starting within 30 days rather than between 31 and 90 days was associated with relative risks of 0.47 for lumbar surgery, 0.72 for advanced imaging and 0.45 for long-term opioid use; repeat emergency visits did not differ significantly. In acute sciatica, a transforaminal epidural steroid injection within eight weeks reduced leg pain modestly, and opioid use was lower in the injection arms, a bridge that spares the drug.

    The nulls belong in the same paragraph. A tertiary department that added a rapid-access physiotherapy clinic to its back-pain pathway saw no significant change in admissions, partly because 41 percent of referred patients attended. An interdisciplinary program for frequent attenders improved present pain faster and reduced aberrant opioid use but did not reduce emergency visits more than usual care. Advanced-access primary care lowered emergency use in all 3 studies that measured it, none significantly. Individualized care plans for frequent users did reduce visit frequency across 13 studies. The pattern favors a same-week visit that is attended and that produces a plan, and that is precisely what patient outcomes depend on.

    Workflow: standing orders and documentation

    Reproducibility comes from a written protocol. A standing order can define the trigger (an emergency discharge for back pain within the prior week), a scripted one-week call on pain and function, and, where pain persists, a visit with a defined terrain measurement set. Staffing and workflow determine whether the call happens at all.

    Documentation carries the rest. Structured results support HEDIS and value-based care documentation and MIPS reporting as quality concepts, and repeat measurements can be trended through chronic care and between-visit monitoring. For repeat presenters, the humility is shared: primary care is often the missing door too, and a measured plan is what turns the follow-up call into one.

    Every figure above, with its design limits, is set out in the book’s chapter companion. The preceding piece in the series covers terrain screening in fibromyalgia and small-fiber pathology.

    Frequently asked questions

    Which discharged back-pain patients need urgent re-evaluation?

    Those who return worse, particularly with fever or new neurological signs. Among 1,381,614 patients discharged with a nonspecific back-pain diagnosis, 0.2 percent returned within 30 days with a serious neurologic condition or died, and intraspinal abscess was the most frequent miss. In confirmed spinal epidural abscess, 71 percent had a potentially related visit in the prior month and only 10 percent showed the classic triad. Review the clinical rationale for structured follow-up.

    Does fasting insulin belong in the follow-up of back pain?

    It belongs in the terrain assessment of the patient whose pain persists, not in the exclusion of red flags. It does not diagnose the back pain; it characterizes the metabolic background that emergency order sets never capture. Paired with glucose, HbA1c and body composition, it gives the treating physician a baseline to trend. See how laboratory and body composition findings are reported.

    How should an emergency opioid prescription be handled at follow-up?

    Document the dispensed duration, the indication and a review date, and leave prescribing decisions with the treating clinician. Duration of the first episode is the variable most closely tied to use at one year, and one-year returns ran higher in patients discharged with an opioid, although that comparison is confounded by pain severity. See how follow-up documentation fits the annual wellness visit.

    Do rapid-access pathways reduce repeat emergency visits?

    Not reliably in controlled evidence so far. A rapid-access physiotherapy clinic did not change admissions with 41 percent attendance, an interdisciplinary program did not reduce visits more than usual care, and advanced access showed nonsignificant reductions. Individualized care plans for frequent users are the most consistent signal, which argues for a plan built on documented findings. Read how standing orders make follow-up reproducible.

    How do results reach the chart?

    Measura reports findings to the ordering physician and does not diagnose disease on its own or treat. Results can be filed as structured data so that terrain measurements sit beside the emergency discharge summary, the one-week call and any referral for a structural diagnosis, which keeps the next clinician from starting over. Learn how results are integrated into the record.

    How common are emergency department visits for low back pain?

    Very common. Low back pain emergency department visits numbered 52.8 million in the United States between 2016 and 2022, roughly one visit in twenty, with a mean presenting pain score of 7.2. The encounter is built to exclude the minority with pathology needing urgent treatment, so most patients reach primary care with mechanism and terrain still unexamined.

    What predicts persistent back pain after an emergency visit?

    Pain at one week is the clearest signal. Among 354 patients from two analgesic trials, pain at the one-week call carried an odds ratio of 2.42 for functional impairment and 3.83 for moderate or severe pain at three months, while a psychosocial risk score added no independent prediction. That makes a scripted one-week call the practical trigger for a terrain visit.

    How soon should physical therapy start after an emergency visit for back pain?

    Early. In 265 patients receiving physical therapy after an emergency back-pain visit, starting within 30 days rather than between 31 and 90 days was associated with relative risks of 0.47 for lumbar surgery, 0.72 for advanced imaging and 0.45 for long-term opioid use. Repeat emergency visits did not differ significantly, so timing works best alongside an attended visit and a plan.

    Build the Follow-Up Door Into Your Practice

    Learn how the Measura protocol fits a post-emergency back-pain pathway, from standing orders and the one-week call to structured terrain results in the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Fellner, A., & Kim, H. S. (2025). Usual Care for Low Back Pain at United States Emergency Departments, 2016-2022. Annals of Emergency Medicine, 86(6), 639–645. https://doi.org/10.1016/j.annemergmed.2025.06.005
    • Downie, A., Hancock, M., Jenkins, H., Buchbinder, R., Harris, I., Underwood, M., Goergen, S., & Maher, C. G. (2020). How common is imaging for low back pain in primary and emergency care? Systematic review and meta-analysis of over 4 million imaging requests across 21 years. British Journal of Sports Medicine, 54(11), 642–651. https://doi.org/10.1136/bjsports-2018-100087
    • Friedman, B. W., Conway, J., Campbell, C., Bijur, P. E., & John Gallagher, E. (2018). Pain One Week After an Emergency Department Visit for Acute Low Back Pain Is Associated With Poor Three-month Outcomes. Academic Emergency Medicine, 25(10), 1138–1145. https://doi.org/10.1111/acem.13453
    • Shah, A., Hayes, C. J., & Martin, B. C. (2017). Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use – United States, 2006-2015. MMWR. Morbidity and Mortality Weekly Report, 66(10), 265–269. https://doi.org/10.15585/mmwr.mm6610a1
    • Schneider, B. J., Doan, L., Maes, M. K., Martinez, K. R., Gonzalez Cota, A., & Bogduk, N. (2020). Systematic Review of the Effectiveness of Lumbar Medial Branch Thermal Radiofrequency Neurotomy, Stratified for Diagnostic Methods and Procedural Technique. Pain Medicine, 21(6), 1122–1141. https://doi.org/10.1093/pm/pnz349
    • Daoust, R., Paquet, J., Marquis, M., Chauny, J. M., Williamson, D., Huard, V., Arbour, C., Émond, M., & Cournoyer, A. (2022). Evaluation of Interventions to Reduce Opioid Prescribing for Patients Discharged From the Emergency Department: A Systematic Review and Meta-analysis. JAMA Network Open, 5(1), e2143425. https://doi.org/10.1001/jamanetworkopen.2021.43425
    • Magel, J., Kim, J., Fritz, J. M., & Freburger, J. K. (2020). Time Between an Emergency Department Visit and Initiation of Physical Therapist Intervention: Health Care Utilization and Costs. Physical Therapy, 100(10), 1782–1792. https://doi.org/10.1093/ptj/pzaa100
    • Davidson, S. R. E., Kamper, S., Haskins, R., Petkovic, D., Feenan, N., Smith, D., O’Flynn, M., Pallas, J. D., Donald, B., Smiles, J. P., Machado, G., Oldmeadow, C., & Williams, C. M. (2026). Impact of strategies to improve flow and lower hospital admissions for low back pain in the emergency department: an interrupted time-series analysis. Emergency Medicine Journal, 43(4), 230–237. https://doi.org/10.1136/emermed-2024-214082
    • Grant, K. L., McParland, A. L., Francispragasam, M., & Oxciano, P. (2023). Referral pathways for chronic pain patients from Canadian emergency departments: emergency physicians’ practices, perspectives, and recommendations. CJEM, 25(9), 761–767. https://doi.org/10.1007/s43678-023-00566-3
    • Wong, C. K., O’Rielly, C. M., Teitge, B. D., Sutherland, R. L., Farquharson, S., Ghosh, M., Robertson, H. L., & Lang, E. (2020). The Characteristics and Effectiveness of Interventions for Frequent Emergency Department Utilizing Patients With Chronic Noncancer Pain: A Systematic Review. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 27(8), 742–752. https://doi.org/10.1111/acem.13934

    Related reading

  • Title card for The Volume Knob Is Not in the Knee, The Pained Brain Chapter 9, with Dr. Padda presenting

    Fibromyalgia and Small Fiber Neuropathy: Screening the Terrain

    The Volume Knob Is Not in the Knee | The Pained Brain, Chapter 9

    Fibromyalgia and Small Fiber Neuropathy: Screening the Terrain

    Screen patients with fibromyalgia or chronic widespread pain for small-fiber involvement, above all to search for a treatable cause. Sudomotor testing gives a noninvasive read on small-fiber function without replacing skin biopsy, while body composition, heart rate variability and laboratory panels measure the terrain around central sensitization.

    Small-fiber pathology turns up in roughly half of fibromyalgia patients, yet it does not account for their sensory findings. That paradox is the clinical case for measuring the terrain around central sensitization.

    Pooled across eight studies and 222 participants, small-fiber pathology is present in 49 percent of fibromyalgia patients, and an independent meta-analysis of 903 patients reproduced the figure. The fibromyalgia small fiber neuropathy overlap is real. It is not, however, the mechanism of the pain: when 57 consecutive fibromyalgia patients were split by biopsy result, clinical measures, sensory testing and evoked potentials did not differ between the groups.

    That result reframes the workup. The fiber loss behaves like residue of a chronically inflamed terrain, while the pain itself is generated upstream by central amplification. Chapter 9 of The Pained Brain, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, presented in the video above, lays out that mechanism. For a primary care, pain, endocrine or geriatric practice, the working questions are narrower: whom to measure, with what, and what a result changes.

    How is central sensitization measured?

    Woolf’s physiological definition describes a prolonged, reversible gain in excitability and synaptic efficacy within central nociceptive circuits. The bedside instruments have published reliability. In 88 participants retested by different raters, pressure pain threshold reached an ICC of 0.77 or better and temporal summation 0.76 or better; conditioned pain modulation is the noisiest of the three, with best intra-session ICCs of 0.64 in healthy subjects and 0.77 in patients. These are quantitative sensory testing protocols, usually run in pain or research settings. Measura [Cardiometabolic and Autonomic Health Analysis] does not perform them.

    The questionnaire most clinics rely on is a different instrument again. Pooled across 66 studies with 13,284 participants, Central Sensitization Inventory scores correlated strongly with depression, anxiety, stress and catastrophizing and weakly or not at all with experimental nociceptive measures. It screens for a syndrome; it does not quantify gain. What an office can quantify reproducibly is the terrain tied to a lowered threshold; see the clinical rationale.

    What terrain drives central sensitization?

    • Visceral adiposity and leptin. In 265 people with knee pain drawn from a population cohort, those with low pressure thresholds had a median visceral fat area of 130 versus 95 square centimeters and leptin of 22.2 versus 13.3 ng/mL. Both remained associated with widespread pain in the normal-BMI subgroup, 12 percent of whom reported chronic widespread pain. CRP, fasting glucose and HbA1c were not associated.
    • Cardiometabolic load before any pain. In 302 healthy adults without a pain condition, a latent load constructed from BMI, mean arterial pressure and heart-rate variability predicted greater spinal facilitation and weaker descending inhibition of the spinal reflex, after control for physical activity, sleep, stress and distress. Perceived pain sensitivity did not shift.
    • Dietary pattern and systemic inflammation. Across nine knee osteoarthritis studies including 1,889 people, higher serum CRP showed indications of association with lower pressure thresholds and with temporal summation, and in 53 patients with nonspecific chronic low back pain a more pro-inflammatory dietary score tracked higher pain sensitivity.

    The social driver sits beside these. Across nineteen studies, perceived stigma correlated with pain intensity, disability and depression, and family invalidation independently raised the odds of the fibromyalgia phenotype (odds ratio 1.81) with depression already in the model. The malingering base rates still in circulation derive from neuropsychologists’ impressions in forensic caseloads, and no validated method detects malingering in chronic pain. The less obvious consequence: an objective terrain finding in the problem list changes how the next clinician reads the same patient, which makes documentation a clinical intervention in its own right.

    Which fibromyalgia patients should be tested for small fiber neuropathy?

    Selection follows phenotype rather than a single code. Reasonable candidates include patients carrying fibromyalgia or chronic widespread pain; osteoarthritis patients whose pain has spread well beyond the affected joint, particularly before a joint-replacement referral; and patients accumulating overlapping pain diagnoses, which in 149,742 rheumatology patients applied to 22.7 percent. See the selection criteria.

    • Sudomotor testing offers a noninvasive read on small-fiber sudomotor function. It does not replace skin biopsy, which remains the tissue diagnosis. The practical reason to pursue small-fiber involvement is the search for a treatable cause: in one biopsy-positive fibromyalgia series, workup identified dysimmune markers in 8 patients and hepatitis C serology in 2.
    • Bioimpedance body composition separates fat and lean compartments when BMI is normal and the history is not.
    • Heart rate variability and cardiac autonomic reflex tests characterize autonomic tone, one of the components of the load construct above. Pooled data also put autonomic small-fiber impairment at 45 percent in fibromyalgia.
    • Laboratory panels extend beyond CRP, because the markers that tracked thresholds in the knee cohort were not the systemic inflammatory ones.

    What does a terrain finding change in treatment?

    Sensitization measured before treatment was associated with outcome in 17 of 25 surgical studies and in all 11 pharmacological studies of one systematic review. Knee replacement candidates with both facilitated temporal summation and impaired inhibition obtained 52.0 percent relief at one year, compared with 81.1 percent and 79.6 percent where only one measure was abnormal. The consolidating review from the same group still grades the association low to moderate and advises against routine clinical use until methods are standardized.

    A terrain finding does not cancel a procedure. After discectomy for lumbar disc herniation, 100 patients improved regardless of sensitization severity. What it changes is sequencing. The metabolic plan is written before the intervention, so that the period of reduced peripheral input is used: after cervical medial branch radiofrequency neurotomy in 53 patients with chronic whiplash, widespread hyperalgesia receded within a month and returned when the nerves regenerated around ten months.

    The terrain lever carries the thinnest design and the largest signal. In 110 completers of a three-month energy-restricted diet, weight fell 7.9 percent and chronic musculoskeletal pain prevalence went from 51 to 25 percent, uncontrolled, with no change in hsCRP. Serial body composition follows that change; the inflammatory marker did not. The humility belongs to interventional pain medicine: its tools were built for the joint, and in these patients the generator had moved.

    Pairing with cognitive assessment and fall prevention

    In 188,594 UK Biobank participants followed thirteen years, self-reported chronic widespread pain carried a hazard ratio of 2.55 for incident mild cognitive impairment and 1.53 for dementia, although the authors’ Mendelian randomization found no causal signal. That supports a documented cognitive assessment baseline in this population, repeated on the same instrument.

    Fall risk enters through the pharmacology. In the Cochrane neuropathic pain pooling, gabapentin produced dizziness in 19 percent with a number needed to harm of 7.5, and pregabalin in fibromyalgia carried a number needed to harm of 3.7 for dizziness. For older patients already taking these agents, vestibular and balance testing documents the baseline the prescriber is weighing; prescribing decisions stay with the treating physician. The cognitive assessment and fall prevention page covers how the two fit together.

    Documentation and workflow

    Reproducibility comes from standing orders: a defined trigger such as fibromyalgia or chronic widespread pain on the problem list, a fixed measurement set, and results routed to the ordering clinician. The annual wellness visit is the natural home for the cognitive baseline and fall-risk documentation, and structured results support MIPS and quality reporting as documentation. Measura measures and reports; interpretation and management remain with the practice.

    Every study cited here, with its design limits, is in the book’s chapter companion. The next piece in the series addresses the patient who arrives in primary care after an emergency visit for back pain.

    Frequently asked questions

    Should every fibromyalgia patient have small-fiber testing?

    Not reflexively. A pooled prevalence near 49 percent is high, but the pathology does not explain the sensory phenotype, so its value lies in the treatable-cause search and a documented baseline. Noninvasive sudomotor measurement fits a primary care workflow, with skin biopsy reserved for cases where the tissue answer would change the workup. See specialty applications of autonomic and sudomotor testing.

    Does a normal CRP argue against central sensitization?

    No. In surgical spine patients, inflammatory proteins were elevated in cerebrospinal fluid while serum proteins ran below controls, and in the knee-pain cohort CRP was unrelated to low thresholds while visceral fat and leptin were related. Serum inflammation and central amplification can diverge, so a normal CRP closes very little. Review how terrain findings are reported.

    Is the Central Sensitization Inventory adequate for screening?

    As a screen for the syndrome it is useful; as a measure of nociceptive gain it is not. It tracks psychological constructs strongly, although a separate meta-analysis of 33 studies found significant correlation with pressure threshold, about half of those effects medium to large. A high score is a reason to measure objectively, not a diagnosis. Read how standing orders make screening reproducible.

    How does autonomic measurement relate to central sensitization?

    Heart-rate variability was one component of the cardiometabolic load that predicted spinal facilitation in adults with no pain, and pooled data place autonomic small-fiber impairment at 45 percent in fibromyalgia. Autonomic testing describes the terrain rather than the amplifier, and it earns its place as a trendable baseline in the record. See autonomic nervous system testing.

    Where do Measura results go?

    Findings are reported to the ordering physician. Measura does not diagnose disease on its own or treat, and it does not make medication decisions. Structured results can be filed into the chart beside the pain history and the cognitive baseline. Learn how results reach the record.

    Can you have fibromyalgia and small fiber neuropathy at the same time?

    Yes, and often. Pooled across eight studies and 222 participants, small-fiber pathology is present in 49 percent of fibromyalgia patients, and an independent meta-analysis of 903 patients reproduced that figure. Pooled data also place autonomic small-fiber impairment at 45 percent. The overlap is real, which is why a noninvasive sudomotor read belongs in the workup of widespread pain.

    Does small fiber neuropathy cause fibromyalgia pain?

    Not on the evidence here. When 57 consecutive fibromyalgia patients were split by biopsy result, clinical measures, sensory testing and evoked potentials did not differ between the groups. The fiber loss behaves like residue of a chronically inflamed terrain, while the pain itself is generated upstream by central amplification. The finding still matters, because the workup can uncover a treatable cause.

    How is small fiber neuropathy diagnosed in fibromyalgia?

    Skin biopsy remains the tissue diagnosis. Sudomotor testing gives a noninvasive read on small-fiber sudomotor function and fits a primary care workflow, but it does not replace biopsy. Heart rate variability and cardiac autonomic reflex tests describe autonomic tone. In one biopsy-positive fibromyalgia series, the workup found dysimmune markers in 8 patients and hepatitis C serology in 2.

    Add Terrain Measurement to the Sensitized Patient Workup

    See how the Measura protocol fits a practice that manages fibromyalgia and widespread pain, from selection criteria and standing orders to reporting into the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Grayston, R., Czanner, G., Elhadd, K., Goebel, A., Frank, B., Üçeyler, N., Malik, R. A., & Alam, U. (2019). A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Seminars in Arthritis and Rheumatism, 48(5), 933-940 (epub 2018-08-23). https://doi.org/10.1016/j.semarthrit.2018.08.003
    • Fasolino, A., Di Stefano, G., Leone, C., Galosi, E., Gioia, C., Lucchino, B., Terracciano, A., Di Franco, M., Cruccu, G., & Truini, A. (2020). Small-fibre pathology has no impact on somatosensory system function in patients with fibromyalgia. Pain, 161(10), 2385–2393. https://doi.org/10.1097/j.pain.0000000000001920
    • Oaklander, A. L., Herzog, Z. D., Downs, H. M., & Klein, M. M. (2013). Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain, 154(11), 2310–2316. https://doi.org/10.1016/j.pain.2013.06.001
    • Adams, G. R., Gandhi, W., Harrison, R., van Reekum, C. M., Wood-Anderson, D., Gilron, I., & Salomons, T. V. (2023). Do “central sensitization” questionnaires reflect measures of nociceptive sensitization or psychological constructs? A systematic review and meta-analyses. Pain, 164(6), 1222–1239. https://doi.org/10.1097/j.pain.0000000000002830
    • Andersson, M. L. E., Thorén, E., Sylwander, C., & Bergman, S. (2023). Associations between chronic widespread pain, pressure pain thresholds, leptin, and metabolic factors in individuals with knee pain. BMC Musculoskeletal Disorders, 24(1), 639. https://doi.org/10.1186/s12891-023-06773-4
    • Rhudy, J. L., Kuhn, B. L., Demuth, M. J., Huber, F. A., Hellman, N., Toledo, T. A., Lannon, E. W., Palit, S., Payne, M. F., Sturycz, C. A., Kell, P. A., Guereca, Y. M., Street, E. N., & Shadlow, J. O. (2021). Are Cardiometabolic Markers of Allostatic Load Associated With Pronociceptive Processes in Native Americans?: A Structural Equation Modeling Analysis From the Oklahoma Study of Native American Pain Risk. The Journal of Pain, 22(11), 1429–1451. https://doi.org/10.1016/j.jpain.2021.04.014
    • Petersen, K. K., Vaegter, H. B., Stubhaug, A., Wolff, A., Scammell, B. E., Arendt-Nielsen, L., & Larsen, D. B. (2021). The predictive value of quantitative sensory testing: a systematic review on chronic postoperative pain and the analgesic effect of pharmacological therapies in patients with chronic pain. Pain, 162(1), 31–44. https://doi.org/10.1097/j.pain.0000000000002019
    • Jiang, X., Johansson, E., Nijs, J., & Wang, X. (2025). Cognitive Decline and Dementia in Chronic Widespread Pain: A Longitudinal Population-based Study. Anesthesiology, 143(6), 1560–1571. https://doi.org/10.1097/ALN.0000000000005731
    • Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S. C., Tölle, T. R., Phillips, T., & Moore, R. A. (2017). Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 6(6), CD007938. https://doi.org/10.1002/14651858.CD007938.pub4
    • Smith, A. D., Jull, G., Schneider, G., Frizzell, B., Hooper, R. A., & Sterling, M. (2014). Cervical radiofrequency neurotomy reduces central hyperexcitability and improves neck movement in individuals with chronic whiplash. Pain Medicine, 15(1), 128–141. https://doi.org/10.1111/pme.12262

    Related reading

  • Dr. Padda presenting beside the chapter title card reading Chronic Stress Is Not in Your Head. It's in Your Pain Threshold, The Pained Brain, Chapter 8

    HPA Axis Dysfunction in Chronic Pain: What to Measure Beyond Cortisol

    Chronic Stress Is Not in Your Head. It's in Your Pain Threshold | The Pained Brain, Chapter 8

    HPA Axis Dysfunction in Chronic Pain: What to Measure Beyond Cortisol

    Screen for HPA axis dysfunction in chronic pain by exposure history and downstream measures rather than a morning cortisol. Glucose, triglycerides, body composition and heart rate variability carry the signal; in one prospective study, triglycerides, waist-to-hip ratio and resting pulse predicted chronic back pain where hair cortisol did not.

    In chronic pain the stress axis runs high in some patients, low in others and flat in many. The screening question is not the cortisol value but which downstream measures carry the signal.

    HPA axis dysfunction is one of the most frequently invoked and least usefully measured concepts in chronic pain care. The instinct is to order a morning cortisol. The evidence says that value will rarely answer the clinical question, because in pain populations the axis is dysregulated in both directions, and what it does downstream is easier to document than the hormone itself.

    The source is Chapter 8 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, and the chapter video above.

    Can a cortisol test diagnose HPA axis dysfunction?

    The most cited prospective study tested the axis in 267 psychologically at-risk adults without chronic widespread pain. Failure to suppress after dexamethasone carried an odds ratio of 3.53 for incident pain, and all three abnormalities together 8.5, but the base was 28 incident cases, and low morning saliva alone was not significant. A larger Dutch cohort of 2,039 adults followed six years found that no HPA measure predicted onset; the count of adverse life events did, at 1.14 per event.

    In established pain the picture is bidirectional. Among 4,560 older English adults, chronic pain was associated with hair cortisol 15 percent higher at the low tail of the distribution and 19 percent higher near the top, with no difference in between. In 99 fibromyalgia patients, perceived stress was markedly higher than in controls while neither salivary nor hair cortisol differed. What does track outcomes is the diurnal slope: across 80 studies and 36,823 participants, a flatter slope was associated with poorer health, most strongly immune and inflammatory outcomes, and with mortality at a hazard of 2.40, or 1.63 after two outliers were removed, with evidence of publication bias.

    The most instructive null came from 140 young adults with intermittent back pain. Hair cortisol was not selected as a predictor of chronic low back pain at one year. The markers that were selected were norepinephrine, interleukin-6, triglycerides, waist-to-hip ratio and resting pulse, with a development AUC of 0.93 falling to 0.88 after bootstrapping and no external validation. The stress system was visible in metabolic and autonomic variables. The hormone concentration was not.

    Can cortisol be normal when the stress axis is not?

    Receptor-level resistance explains part of the gap. In 33 caregivers of family members with glioblastoma, monocytes showed 1.65-fold greater NF-κB binding-motif prevalence and 0.68-fold lower glucocorticoid receptor motif prevalence, with diurnal cortisol and receptor protein similar to controls. The same study found no group difference in functional sensitivity once normalized, so this is transcriptional rather than demonstrated functional resistance. The practical point is that a reassuring cortisol value can coexist with an inflammatory phenotype.

    Which life exposures point to HPA axis dysfunction?

    Exposure history identifies risk better than a hormone draw, and almost none of it is on a standard intake form. Reasonable criteria in a pain or primary care population include:

    • Adverse childhood experience: across 85 studies and 826,452 adults the adjusted odds of adult chronic pain were 1.45, graded from 1.29 for one experience to 1.95 for four or more, although most included studies were cross-sectional.
    • Sustained financial hardship: hardship at 43 predicted chronic widespread pain at 68 with a relative risk of 4.44 in the most hard-pressed group, adjusted for measured body mass and psychiatric caseness.
    • High perceived occupational stress: among 715 healthcare workers without baseline back pain, high stress carried an odds ratio of 2.67 for low back pain a year later.
    • Loneliness rather than living alone: in 315,197 UK Biobank participants, loneliness carried a hazard of 1.32 for low back pain after broad adjustment, while objective isolation raised nothing.
    • Caregiving and job strain, which also carry metabolic risk: job strain raised the hazard of type 2 diabetes 1.15-fold across 124,808 adults, and three or more work-stress exposures carried 2.25 times the odds of the metabolic syndrome among 10,308 civil servants.

    These map onto the practice criteria in selection criteria for testing. The ten-item Perceived Stress Scale, banded 0-9 low, 10-19 moderate and 20-40 high in the prospective work, is a reasonable repeated documentation field alongside them.

    What should be measured instead of cortisol?

    The downstream record is where Measura [Cardiometabolic and Autonomic Health Analysis] fits. It is a measurement protocol reported to the ordering physician, not a diagnostic or treatment service in its own right.

    • Laboratory panels for glucose, triglycerides and related metabolic markers, the variables that carried prospective signal where cortisol did not.
    • Bioimpedance body composition to document fat and lean compartments, since waist circumference in the hair-cortisol cohorts is a proxy rather than a measure of visceral fat.
    • Heart rate variability as an autonomic baseline. Across 52 studies of chronic primary pain, higher baseline cortisol accompanied lower recovery heart rate variability, at very low to moderate certainty.
    • Cardiac autonomic reflex tests where symptoms suggest broader autonomic involvement beyond resting variability.
    • A cognitive assessment baseline in older patients, given the imaging association between higher cortisol and smaller hippocampal volume in chronic back pain.

    Trapezius pressure-pain algometry, which tracked perceived stress in 2,199 adults, is a clinic test outside this library.

    What a finding changes

    A documented pattern moves stress from a dismissal to a treatment target, and the sober effect sizes belong in the conversation. In 342 adults with chronic low back pain, mindfulness-based stress reduction produced meaningful functional improvement in 60.5 percent at 26 weeks, cognitive behavioral therapy in 57.7 percent and usual care in 44.1 percent. Pain reprocessing therapy left 66 percent of 151 adults with mild to moderate back pain at or near zero pain against 20 percent with placebo injection. Against an active control, the Cochrane estimate for cognitive behavioral therapy on pain intensity was only 0.09, which argues for setting expectations around function and distress. In 73 adults with PTSD and chronic pain, heart rate variability biofeedback cut pain interference 24.9 percent without a between-group difference in intensity, a direct reason to repeat the autonomic measure.

    Interventional care belongs in the same plan. Of 14 back pain patients rescanned six months after spine surgery or facet injection, left dorsolateral prefrontal thickness had recovered in step with falling pain and disability. Quieting the signal buys the window for retraining the axis; repeat measures show whether the terrain moved.

    Documentation and workflow

    Dr. Padda’s position is that the profession has to stop charting stress as a verdict: in a survey of people with chronic pain, 77 percent described provider invalidation, which was associated with poorer physical function. Writing the mechanism into the record, with exposures and measures attached, is the correction. A standing order triggered by a documented exposure plus a pain diagnosis makes the workup reproducible; see standing orders for screening. The annual wellness visit is the natural repeat point, covered in annual wellness visit integration, and the same cardiometabolic documentation supports MIPS and HEDIS quality concepts. Unmeasured is unmanaged. Study-level detail is in the Chapter 8 companion supplement, the sleep side of the same clock is sleep deprivation and insulin resistance screening, and a patient-facing version is available for handouts.

    Frequently asked questions

    Is a morning serum cortisol useful for suspected HPA axis dysfunction in chronic pain?

    Rarely on its own. The prospective signal came from failed dexamethasone suppression, not a morning level, and a larger cohort found no HPA measure predicted onset. Population data show associations at both tails of the cortisol distribution, and fibromyalgia samples show normal or low values. The diurnal slope and downstream metabolic and autonomic markers are more informative. Interpreting the report.

    Which exposures should prompt a stress-axis workup?

    Graded adverse childhood experience, sustained financial hardship, high perceived work stress, loneliness, caregiving and job strain all carry prospective or dose-dependent associations with chronic pain or metabolic disease. None appear on a typical intake form. Documenting them as structured fields, with a repeated Perceived Stress Scale score, gives a standing order something objective to trigger on. Why metabolic health belongs in a pain practice.

    Where does heart rate variability fit?

    It measures the autonomic arm of the stress response, which cortisol does not capture. In chronic primary pain, higher cortisol accompanied lower recovery heart rate variability across 52 studies, and resting pulse was among the variables that predicted chronic back pain where hair cortisol failed. It also gives a repeatable measure when biofeedback or behavioral treatment is used. Specialty applications.

    How should the results be documented?

    As mechanism, not as a label. Record the exposures, the perceived stress score, the metabolic and body composition values and the autonomic measures in structured fields so they can be trended and repeated at the annual wellness visit. That turns a note reading stress into a measurable problem list entry. Getting results into the record.

    Does treating the pain change the stress-related brain findings?

    Imaging suggests it can. Ten hip arthritis patients rescanned after joint replacement left them without pain showed gray matter increases in four regions within six weeks to four months, and back pain patients showed prefrontal cortex recovery six months after interventional or surgical treatment. Both samples are small, without sham control. What changes for the patient.

    Can HPA axis dysfunction cause low cortisol as well as high?

    Yes. In chronic pain the stress axis runs high in some patients, low in others and flat in many. Among 4,560 older English adults, chronic pain went with higher hair cortisol at both the low tail and the top of the distribution, with no difference in the middle. In fibromyalgia, perceived stress was markedly higher while salivary and hair cortisol did not differ from controls.

    How is HPA axis dysfunction diagnosed in chronic pain?

    Not with a single morning cortisol. The prospective signal came from failed dexamethasone suppression, and what tracks outcomes is a flatter daily cortisol slope. In practice, screening starts with exposure history and then documents the downstream record: glucose, triglycerides, body composition and heart rate variability. In one prospective study, triglycerides, waist-to-hip ratio and resting pulse predicted chronic back pain where hair cortisol did not.

    Can chronic stress lead to back pain?

    The prospective data say it can. Among 715 healthcare workers without back pain, high perceived work stress carried an odds ratio of 2.67 for low back pain a year later. Loneliness carried a hazard of 1.32 for low back pain in 315,197 UK Biobank participants, and sustained financial hardship at 43 predicted chronic widespread pain at 68 with a relative risk of 4.44.

    Turn stress into a measured problem list entry

    Learn how the Measura protocol fits a pain or primary care practice, from exposure-based selection criteria to results documented in the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • McBeth, J., Silman, A. J., Gupta, A., Chiu, Y. H., Ray, D., Morriss, R., Dickens, C., King, Y., & Macfarlane, G. J. (2007). Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study.
    • Generaal, E., Vogelzangs, N., Macfarlane, G. J., Geenen, R., Smit, J. H., de Geus, E. J., Penninx, B. W., & Dekker, J. (2015). Biological stress systems, adverse life events and the onset of chronic multisite musculoskeletal pain: a 6-year cohort study.
    • Adam, E. K., Quinn, M. E., Tavernier, R., McQuillan, M. T., Dahlke, K. A., & Gilbert, K. E. (2017). Diurnal cortisol slopes and mental and physical health outcomes: A systematic review and meta-analysis.
    • Miller, G. E., Murphy, M. L. M., Cashman, R., Ma, R., Ma, J., Arevalo, J. M. G., Kobor, M. S., & Cole, S. W. (2014). Greater inflammatory activity and blunted glucocorticoid signaling in monocytes of chronically stressed caregivers.
    • Bussières, A., Hancock, M. J., Elklit, A., Ferreira, M. L., Ferreira, P. H., Stone, L. S., Wideman, T. H., Boruff, J. T., Al Zoubi, F., Chaudhry, F., Tolentino, R., & Hartvigsen, J. (2023). Adverse childhood experience is associated with an increased risk of reporting chronic pain in adulthood: a stystematic review and meta-analysis.
    • Ma, X., Song, X., Zou, Y., Zhang, D., Yang, B., Lei, B., Zhou, J., Zhao, X., Xiang, R., Qu, Y., Zheng, S., Yu, T., Han, T., Zhong, Y., Xia, M., Fan, M., Jiang, X., & Zhang, B. (2026). Loneliness, traditional risk factor control, genetic predisposition, and development of musculoskeletal disorders.
    • Vyverman, J., De Baere, R., Timmers, I., Coppieters, I., Van Oosterwijck, J., & Moerkerke, M. (2026). The stress-pain connection in chronic primary pain: A systematic review and meta-analysis of physiological stress markers in relation to experimental pain responses.
    • Cherkin, D. C., Sherman, K. J., Balderson, B. H., Cook, A. J., Anderson, M. L., Hawkes, R. J., Hansen, K. E., & Turner, J. A. (2016). Effect of Mindfulness-Based Stress Reduction vs Cognitive Behavioral Therapy or Usual Care on Back Pain and Functional Limitations in Adults With Chronic Low Back Pain: A Randomized Clinical Trial.
    • Williams, A. C. de C., Fisher, E., Hearn, L., & Eccleston, C. (2020). Psychological therapies for the management of chronic pain (excluding headache) in adults.
    • Seminowicz, D. A., Wideman, T. H., Naso, L., Hatami-Khoroushahi, Z., Fallatah, S., Ware, M. A., Jarzem, P., Bushnell, M. C., Shir, Y., Ouellet, J. A., & Stone, L. S. (2011). Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function.

    Related reading

  • Dr. Padda presenting beside the chapter title card reading Why Pain Is Worst at 3 a.m., The Pained Brain, Chapter 7

    Sleep Deprivation and Insulin Resistance: Who to Screen in Pain Care

    Why Pain Is Worst at 3 a.m. | The Pained Brain, Chapter 7

    Sleep Deprivation and Insulin Resistance: Who to Screen in Pain Care

    Screen for insulin resistance in chronic pain patients who report insomnia, frequent night waking or poor sleep quality, work night or rotating shifts, or take a nightly opioid. Fasting glucose and HbA1c alone miss the compensated phase, so the workup adds fasting insulin and triglycerides.

    Four nights of restricted sleep measurably lower insulin sensitivity in healthy adults. In a pain population that sleeps in fragments, that makes the sleep history a metabolic screening trigger, not a lifestyle note.

    The evidence on sleep deprivation insulin resistance is no longer epidemiology alone. Hyperinsulinemic clamp studies in healthy adults show whole-body insulin sensitivity falling within four to five nights of restriction, and the fall is larger when the sleep is also mistimed. For a physician managing chronic pain, the implication is operational: a patient who reports broken sleep is carrying a metabolic exposure that the usual fasting glucose will detect late, if at all.

    The clinical argument comes from The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, in the chapter whose video is titled Why Pain Is Worst at 3 a.m. What follows translates it into screening terms: the effect sizes worth knowing, who meets a reasonable threshold for testing, what a result changes, and how to make it reproducible in a busy practice.

    How much does sleep loss lower insulin sensitivity?

    Magnitudes first. In 14 healthy adults, five nights of 4 hours against 8 lowered whole-body insulin sensitivity 25 percent and peripheral sensitivity 29 percent, with 24-hour urinary cortisol up 21 percent. In postmenopausal women, four nights of restriction cut clamp sensitivity 20 percent at the low insulin dose. Adipocytes biopsied from seven lean young adults after four nights at 4.5 hours needed nearly three times the insulin for half-maximal signaling, a 30 percent drop in total signaling response against a 16 percent drop in whole-body sensitivity. Pooled across 41 randomized trials of sleep restriction, the standardized effect on insulin sensitivity was -0.70.

    Timing is a separate insult. Held to identical short sleep, men whose sleep was also shifted lost 58 percent of insulin sensitivity against 32 percent when aligned, and hsCRP rose 146 percent against 64. With the whole day moved 12 hours out of phase, glucose rose only 6 percent despite 22 percent more insulin, and 3 of 8 participants reached a prediabetic postprandial range. That compensation is the screening problem in miniature.

    These are small samples of healthy volunteers over days, and the misalignment effect was significant in men only. None enrolled chronic pain patients. What they establish is mechanism and direction, and the population data supply the rest: each hour of sleep below seven carried 1.09 times the risk of type 2 diabetes across 482,502 participants, and night-shift work carried 1.30 times the hazard across ten cohorts.

    Sleep deprivation insulin resistance: who meets the threshold for testing

    Sleep disturbance and chronic musculoskeletal pain predict each other. In a 20-cohort meta-analysis of 208,190 adults, baseline sleep problems predicted incident pain at an odds ratio of 1.79, and baseline pain predicted incident sleep problems at 2.02. In daily reporting over six months in 801 adults, the sleep-to-pain path was the stronger one, and quality rather than duration carried it. Reasonable selection criteria include:

    • Chronic pain with insomnia, frequent nocturnal awakening or self-reported poor sleep quality.
    • Night-shift or rotating work, noting that the pooled diabetes association was significant in women and not in men, and that nurses showed no significant pain association once pooled.
    • Nightly opioid therapy: central sleep apnea affects about 24 percent of chronic opioid users, and in a multi-clinic cohort 58.8 percent of opioid-treated pain patients who completed a sleep study had sleep apnea, of whom only a quarter of the newly diagnosed received treatment.
    • Sedative-hypnotic use in older adults, for reasons covered under falls below.
    • Reported loss of strength or muscle, given that sarcopenia carried 1.26 times the odds of chronic pain in pooled adjusted data.

    The social determinants are part of the selection, not an afterthought. Shift rosters, lit bedrooms and irregular schedules are occupational and economic exposures before they are behaviors. The practice-level criteria in selection criteria for testing map onto these groups directly.

    What changes in management when sleep loss is found?

    The first change is what gets measured. Fasting glucose and HbA1c alone will miss the compensated phase that the misalignment data describe, so a metabolic workup in this group reasonably adds fasting insulin and triglycerides through laboratory panels. Bioimpedance body composition documents lean and fat mass, which matters because overweight adults dieting on 5.5 hours of sleep lost 60 percent more lean mass than on 8.5, and because the NHANES analysis linking 10 percent more muscle to 11 percent lower HOMA-IR estimated muscle by impedance. Heart rate variability gives an autonomic baseline in a population in which six nights of restriction raised sympathetic activity.

    The second change is sequencing. The practice position in the source material is that the sleep history is taken with the pain history, an apnea screen precedes the first opioid prescription, and a sleep study precedes dose escalation. That is a practice-reported position from our own population, not a trial outcome, and individual results vary. Polysomnography is outside the Measura [Cardiometabolic and Autonomic Health Analysis] library and is ordered separately; the value of pairing it with metabolic testing is that the same patient’s apnea, insulin and body composition are documented together rather than in three silos.

    The third change is expectation setting. Cognitive behavioral therapy for insomnia produced a standardized 0.89 improvement in sleep and only 0.20 in pain across 12 trials, yet roughly a third of fibromyalgia patients achieved more than 30 percent pain reduction, and only the sleep-treated group held it at six months. Repeat metabolic measurement is how a clinician sees whether the terrain moved even when the pain score has not.

    Pairing with fall prevention and cognitive assessment

    The patients most likely to be sleeping badly on medication are also the patients at fall risk. Z-drug users carried 1.63 times the odds of fracture across 14 studies, and hip fracture risk ran roughly 2.4-fold for new users of both benzodiazepines and Z-drugs. Vestibular and balance testing belongs in the same encounter for older adults on sedative-hypnotics, and a cognitive assessment baseline gives the prescriber something to compare against when sedating regimens are reviewed. The integration model is laid out in cognitive assessment and fall prevention.

    Documentation and workflow

    Screening only works when it is reproducible. A standing order that fires on a documented sleep complaint in a chronic pain patient removes the dependence on one clinician remembering to ask; the template is in standing orders for screening. Record sleep as two fields, hours and awakenings, because fragmentation removed endogenous pain inhibition at matched sleep loss while consolidated restriction did not. Results belong in the structured record, and the annual wellness visit is a natural point to repeat the panel; see annual wellness visit integration. Where fall risk screening and cardiometabolic measures are tracked for MIPS or HEDIS, the same documentation supports those quality concepts without a separate workflow.

    Dr. Padda directs the sharpest criticism at his own specialty: prescribing for pain while ignoring the clock was, in his words, a failure of care. The corrective is not a lecture on sleep hygiene. It is a measured baseline and a scheduled repeat. Unmeasured is unmanaged. The primary studies and their design limits are collected in the Chapter 7 companion supplement, the stress-axis companion is HPA axis dysfunction as a screening problem, and a patient-facing version is available to share.

    Frequently asked questions

    How quickly does sleep restriction affect insulin sensitivity?

    Within days. Clamp studies in healthy adults show a 25 percent fall in whole-body insulin sensitivity after five nights of four hours and a 20 percent fall after four nights in postmenopausal women. A single night of total deprivation did not change inflammatory markers in pooled data, while three or more nights of about 4.5 hours raised interleukin-6 and CRP. Chronic patterns, not isolated nights, are the screening target. The clinical rationale for cardiometabolic testing.

    Why is fasting glucose insufficient in these patients?

    Because compensation hides the defect. In circadian misalignment, glucose rose only 6 percent while insulin rose 22 percent, and in a time-restricted eating crossover in men with prediabetes, insulin and insulin resistance improved while glucose did not change. A glucose-only protocol misclassifies both the exposure and the response. Adding fasting insulin and body composition captures the compensated phase. Interpreting the report.

    Should opioid-treated patients be screened for sleep apnea before metabolic testing?

    They are parallel questions, not sequential ones. Pooled referral data put central apnea near 24 percent in chronic opioid users, with risk concentrated at higher daily morphine-equivalent doses, and polysomnography is ordered separately. Metabolic and autonomic testing can proceed alongside it, so the same chart documents breathing, insulin and body composition together. Specialty applications in pain and primary care.

    Does shift work justify metabolic screening on its own?

    It is a reasonable contributing criterion. Night-shift work carried 1.30 times the hazard of type 2 diabetes across ten cohorts, significant in women, with a gradient by years of exposure. Nurses, the best-measured shift population, showed no significant pooled association with musculoskeletal pain, so the metabolic signal is stronger than the pain signal. Combine it with sleep complaints or pain rather than using it alone. Making screening reproducible with standing orders.

    Can a lack of sleep cause diabetes?

    Short sleep raises the risk. Across 482,502 participants, each hour of sleep below seven carried 1.09 times the risk of type 2 diabetes, and night-shift work carried 1.30 times the hazard across ten cohorts. Clamp studies show the mechanism: insulin sensitivity falls within four to five nights of restricted sleep, and when sleep was shifted out of phase, glucose rose only 6 percent while insulin rose 22 percent. That compensated phase is what screening should catch.

    Does poor sleep make chronic pain worse?

    Sleep and pain drive each other. In a 20-cohort meta-analysis of 208,190 adults, baseline sleep problems predicted new pain at an odds ratio of 1.79, and baseline pain predicted new sleep problems at 2.02. In six months of daily reporting from 801 adults, the sleep-to-pain path was the stronger one, and sleep quality mattered more than hours. Fragmented sleep also removed the body’s own pain inhibition.

    Does the timing of sleep matter, or only the hours?

    Timing matters on its own. Held to the same short sleep, men whose sleep was also shifted out of its normal window lost 58 percent of insulin sensitivity, against 32 percent when their sleep stayed aligned, and the inflammatory marker hsCRP rose 146 percent against 64. That is why night and rotating shift work belong in the selection criteria for metabolic testing, alongside insomnia and frequent waking.

    Build sleep into your metabolic screening

    Learn how the Measura protocol fits a pain or primary care practice, from selection criteria and standing orders to results in the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Rao, M. N., Neylan, T. C., Grunfeld, C., Mulligan, K., Schambelan, M., & Schwarz, J.-M. (2015). Subchronic sleep restriction causes tissue-specific insulin resistance.
    • Broussard, J. L., Ehrmann, D. A., Van Cauter, E., Tasali, E., & Brady, M. J. (2012). Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study.
    • Zhu, B., Shi, C., Park, C. G., Zhao, X., & Reutrakul, S. (2019). Effects of sleep restriction on metabolism-related parameters in healthy adults: A comprehensive review and meta-analysis of randomized controlled trials.
    • Leproult, R., Holmbäck, U., & Van Cauter, E. (2014). Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss.
    • Santos, M., Gabani, F. L., de Andrade, S. M., Bizzozero-Peroni, B., Martínez-Vizcaíno, V., González, A. D., & Mesas, A. E. (2023). The bidirectional association between chronic musculoskeletal pain and sleep-related problems: a systematic review and meta-analysis.
    • Xie, F., Hu, K., Fu, R., Zhang, Y., Xiao, K., & Tu, J. (2024). Association between night shift work and the risk of type 2 diabetes mellitus: a cohort-based meta-analysis.
    • Wasef, S., Mir, S., Ryan, C., Waseem, R., Bellingham, G., Kashgari, A., Wong, J., & Chung, F. (2021). Treatment for patients with sleep apnea on opioids for chronic pain: results of the OpSafe trial.
    • Nedeltcheva, A. V., Kilkus, J. M., Imperial, J., Schoeller, D. A., & Penev, P. D. (2010). Insufficient sleep undermines dietary efforts to reduce adiposity.
    • Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017). Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis.
    • Selvanathan, J., Pham, C., Nagappa, M., Peng, P. W. H., Englesakis, M., Espie, C. A., Morin, C. M., & Chung, F. (2021). Cognitive behavioral therapy for insomnia in patients with chronic pain – A systematic review and meta-analysis of randomized controlled trials.

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card reading Sugar Is Turning Your Tissues to Glass, The Pained Brain, Chapter 6

    Carpal Tunnel and Diabetes: Hand Diagnoses as Screening Triggers

    Sugar Is Turning Your Tissues to Glass | The Pained Brain, Chapter 6

    Carpal Tunnel and Diabetes: Hand Diagnoses as Screening Triggers

    Carpal tunnel syndrome is a diabetes screening trigger: across more than 37 million people, diabetes carried adjusted odds of 1.69 for it. Test any patient with carpal tunnel, trigger finger, Dupuytren’s contracture, frozen shoulder or tendinopathy, with a lower threshold when two coexist or carpal tunnel appears under age 40.

    Entrapments and capsular stiffness cluster in dysglycemia, and genetic data now place glycemia upstream. That makes the hand and shoulder visit a screening point most practices let pass.

    Carpal tunnel and diabetes are usually documented in different parts of the chart by different clinicians, which is how the carpal tunnel diabetes link goes unread. The hand surgeon releases the ligament, the endocrinologist does not see the patient until the A1c crosses a line, and the problem list accumulates musculoskeletal diagnoses that nobody reads as a glycemic signal. The video above is Chapter 6 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, which traces advanced glycation end products into tendon, capsule and nerve tunnel. The screening questions are who to test when one of these diagnoses appears, what to measure, and what a result changes before the next injection or release.

    How strongly is carpal tunnel linked to diabetes?

    Pooling 25 studies and 92,564 individuals, diabetes carried unadjusted odds of 1.97 for carpal tunnel syndrome or release, and adjusted odds of 1.69 across 18 studies covering more than 37 million people, with no difference between type 1 and type 2. A 2026 propensity-matched analysis of roughly 6.5 million insured US adults gave hazards of 1.35 for incident carpal tunnel and 1.28 for tarsal tunnel, rising to 1.68 for carpal tunnel under age 40. Adhesive capsulitis is five times more likely in diabetes, with a prevalence of 13.4 percent, and 30 percent of patients presenting with it have diabetes.

    The digital diagnoses cluster as well. Comparing 2,250 patients with coded trigger finger against 398,495 without, trigger finger carried odds of 9.59 for coexisting carpal tunnel and 4.89 for Dupuytren’s. Dupuytren’s prevalence runs 31 percent with diabetes versus 14 percent without.

    Does high blood sugar come before carpal tunnel?

    Observational pooling cannot establish direction; Mendelian randomization goes further. Using variants that set lifelong HbA1c in about 379,700 unrelated Europeans, each 10 mmol/mol of genetically predicted A1c carried odds of 1.20 for carpal tunnel, 1.30 for trigger finger, 1.17 for Dupuytren’s and 1.50 for frozen shoulder. In 139 carriers of pathogenic GCK mutations, who live with mildly raised fasting glucose from birth, carpal tunnel odds were 2.86 and frozen shoulder odds 7.16. Limits: European ancestry, healthy-volunteer bias, and no ability to say whether lowering glucose now reverses risk. The direction of cause, though, is no longer the open question.

    Can a normal A1c rule out diabetic changes in the hand?

    For years I read prediabetic A1c values as reassurance. The musculoskeletal data are a large part of why I stopped, and they expose a second-order screening problem. In 100 adults with prediabetes against 50 controls, hand function was worse and limited joint mobility more prevalent, associated with carpal tunnel and trigger finger, yet A1c, fasting glucose and two-hour glucose showed no relationship to hand function. In 158 adults without diabetes or metabolic syndrome, matched on sex, age, body mass and activity, those at a mean A1c of 40.28 versus 34.34 mmol/mol had poorer Achilles collagen quality on MRI and slower gait. In controlled type 2 diabetes, Achilles stiffness ran 8.3 against 5.6 Nm/mm with stiffness tracking A1c, yet without a difference in measured serum or skin AGE.

    Skin autofluorescence is often proposed as the shortcut. It is a separate optical test that Measura [Cardiometabolic and Autonomic Health Analysis] does not perform, and in 4,181 primary-care recruits it performed poorly as a prediabetes screen, with an area under the curve of 0.52. The consequence is that a glycemic number identifies exposure but does not tell you whose collagen, nerve or muscle has already changed. Functional measurement is what separates those patients.

    Carpal tunnel diabetes screening: who to test and what to measure

    • Any patient with carpal tunnel syndrome, trigger finger, Dupuytren’s contracture, adhesive capsulitis or tendinopathy, with a lower threshold when two coexist or when carpal tunnel appears under age 40.
    • Patients scheduled for intra-articular steroid, rotator cuff repair, carpal tunnel release or knee arthroplasty whose glycemic and insulin status is undocumented.
    • Patients whose A1c carries a prediabetes label that never generated further workup.

    Laboratory panels establish A1c and fasting insulin together. Sudomotor testing assesses sweat-gland function supplied by small nerve fibers in the hands and feet; it does not diagnose an entrapment, but it addresses the diffuse small-fiber question in a population where, among 62 people with type 2 diabetes, skin AGE burden tracked reduced sciatic nerve structural integrity. Bioimpedance body composition quantifies lean and fat compartments, and vestibular and balance testing documents postural stability. Results return to the treating physician and inform care; they do not replace electrodiagnostic or surgical evaluation.

    What changes before an injection or carpal tunnel surgery?

    The most immediate change is procedural planning. A single 40-milligram triamcinolone injection in 33 patients with knee osteoarthritis and type 2 diabetes raised mean daily glucose from 161.7 to 198.8 mg/dL over days one to three, with 49.9 percent of hours above 180; across seven published series every study showed a rise, some peaking near 500, most within 24 to 72 hours. Rotator cuff retear ran 28.2 percent in diabetes against 19.3 percent, and 40.0 percent at an A1c of 7.0 or above against 14.6 percent in non-diabetics, although that subgroup rests on two studies. After carpal tunnel release, symptom scores matched, but wrist-to-palm sensory conduction improved 4.31 m/s less in diabetics.

    None of this argues against the procedure; a compressed nerve needs decompression. It argues for injections as a bridge, the fewest that keep the patient functional, with glucose and insulin known in advance, and for coordinated glycemic management around surgery. No agent has dissolved a glucosepane cross-link in a living person: pimagedine missed its primary endpoint and alagebrium did not lower the skin reading. What has been shown is slower, less accumulation in skin collagen years later among type 1 patients randomized to intensive control. On the dietary side, a year of low-AGE eating took HOMA-IR from 3.1 to 1.9 in 138 obese adults with metabolic syndrome, and 13 randomized trials pooled to a HOMA-IR reduction of 1.204; no trial has yet tested that diet against a pain endpoint.

    Pairing with fall prevention

    Glycation is a musculoskeletal problem beyond the hand. In 2,744 adults with a mean age of 74, each unit of skin autofluorescence carried odds of 2.01 for confirmed sarcopenia, with lower appendicular lean mass, weaker grip and slower gait. Observational, but it places the diabetic hand in the same patient as the future fall. A practice already running cognitive assessment and fall prevention can add body composition and balance measurement to that visit rather than ordering them after an injury.

    Workflow and documentation

    These diagnoses are already coded, which makes them usable triggers. A standing order that fires on a new entrapment, trigger digit or adhesive capsulitis diagnosis removes dependence on individual recall. The annual wellness visit is the natural place to reconcile a problem list full of musculoskeletal diagnoses with a glycemic workup that never happened. The patient version of this evidence is frozen shoulder and diabetes: the numbers worth checking; the study-level appraisal is on the Chapter 6 book companion page; and the omega-6 argument that precedes it is in screening chronic NSAID users.

    Frequently asked questions

    Is skin autofluorescence a useful screen in these patients?

    As a population risk marker it predicts outcomes, but as a prediabetes screen it failed in 4,181 primary-care recruits, with an area under the curve of 0.52. It records roughly a decade of glycemic exposure and, in people without disease, much of its cardiovascular signal is explained by age, smoking and body mass. It is also not a Measura test. Clinical rationale.

    Does a near-normal A1c rule out a glycation contribution?

    No. Prediabetic hand dysfunction showed no relationship to A1c or glucose measures, and Achilles collagen quality already differed at a mean A1c of 40.28 versus 34.34 mmol/mol. The genetic data are graded per 10 mmol/mol across the range rather than at a cutoff. Treat the musculoskeletal diagnosis itself as the indication. Selection criteria.

    Should intra-articular steroids be withheld in dysglycemic patients?

    Not reflexively. A compressed nerve or locked joint may need that relief. The glucose excursion is real, 37.1 mg/dL on average over three days after triamcinolone in type 2 diabetes, with peaks near 500 in some series, so the decision benefits from known glucose and insulin status, counseling, and the fewest doses that keep the patient functional. What changes for the patient.

    Where does sudomotor testing fit when the complaint is an entrapment?

    It answers a different question from nerve conduction at the wrist. An entrapment is focal; the glycemic process that raised its likelihood also affects small fibers diffusely, and skin AGE burden has tracked sciatic nerve structural damage in type 2 diabetes. Sudomotor testing documents small-fiber function so a diffuse neuropathy is not missed behind a focal diagnosis. Specialty applications.

    Does intensive glucose control reverse existing cross-links?

    Not on current evidence. In a type 1 diabetes trial, intensive control meant less skin collagen glycation years later, which is reduced accumulation rather than regression. Skin readings did not regress in the first year after bariatric surgery. Follow-up should therefore track function and trajectory, not expect the store to clear. Chronic care and between-visit monitoring.

    Can diabetes cause carpal tunnel syndrome?

    The evidence points that way. Across more than 37 million people, diabetes carried adjusted odds of 1.69 for carpal tunnel. Genetic studies of about 379,700 people found that each 10 mmol/mol of genetically higher lifelong A1c carried carpal tunnel odds of 1.20, and people born with mildly raised fasting glucose from GCK mutations had odds of 2.86. Blood sugar sits upstream of the wrist.

    What is the difference between carpal tunnel and diabetic nerve damage?

    Carpal tunnel is focal: one nerve is squeezed at the wrist, and nerve conduction testing at the wrist looks at it. The blood sugar process that makes carpal tunnel more likely also affects small nerve fibers throughout the hands and feet. Sudomotor testing documents that small-fiber function, so a body-wide neuropathy is not missed behind the wrist diagnosis. The two can exist in the same patient.

    Does carpal tunnel surgery work as well if you have diabetes?

    For symptoms, yes. After carpal tunnel release, people with diabetes reported the same symptom relief as people without it, but sensory nerve conduction from wrist to palm improved 4.31 m/s less. A compressed nerve still needs decompression. The finding argues for knowing glucose and insulin status before the release and for coordinated blood sugar management around the operation, not for skipping it.

    See how the protocol fits your practice

    Learn how Measura testing can sit behind a standing order for hand and shoulder diagnoses, from selection criteria to results in the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Pourmemari, M. H., & Shiri, R. (2016). Diabetes as a risk factor for carpal tunnel syndrome: a systematic review and meta-analysis. Diabetic Medicine, 33(1), 10-16. https://doi.org/10.1111/dme.12855
    • Rydberg, M., Lakhlani, D., Sutjiadi, B. J., Fox, P. M., & Curtin, C. (2026). Diabetes and the risk of entrapment neuropathies of the upper and lower extremity – A propensity score-matched cohort study. Journal of Diabetes and Its Complications, 40(8), 109364. https://doi.org/10.1016/j.jdiacomp.2026.109364
    • Green, H. D., Burden, E., Chen, J., Evans, J., Patel, K., Wood, A. R., Beaumont, R. N., Tyrrell, J., Frayling, T. M., Hattersley, A. T., Oram, R. A., Bowden, J., Barroso, I., Smith, C., & Weedon, M. N. (2024). Hyperglycaemia is a causal risk factor for upper limb pathologies. International Journal of Epidemiology, 53(1), dyad187. https://doi.org/10.1093/ije/dyad187
    • Guggenheim, L., Kang, Y., Furniss, D., & Wiberg, A. (2024). Identifying non-genetic factors associated with trigger finger. Journal of Plastic, Reconstructive & Aesthetic Surgery, 94, 91-97. https://doi.org/10.1016/j.bjps.2024.04.066
    • Erol, K., Akyıldız Tezcan, E., Topaloğlu, U. S., & Göl, M. F. (2025). Diabetic Hand Complications in Prediabetes: A Controlled Observational Study. Archives of Physical Medicine and Rehabilitation, 107(5), 868-874. https://doi.org/10.1016/j.apmr.2025.07.006
    • Magris, R., Monte, A., Vigolo, N., Nardello, F., Trinchi, M., Negri, C., Gisondi, P., Cosma, C., Sartore, G., Lapolla, A., Moghetti, P., & Zamparo, P. (2026). Impact of controlled type 2 diabetes on muscle-tendon mechanics. Acta Diabetologica, 63(7), 1239-1246. https://doi.org/10.1007/s00592-026-02705-5
    • Sánchez, E., Kerkeni, M., Hernández, M., Gavaldà, R., Rius, F., Sauret, A., Torres, G., Bermúdez-López, M., Fernández, E., Castro-Boqué, E., Purroy, F., Mauricio, D., Farràs-Sallés, C., Buti, M., Godoy, P., Pamplona, R., & Lecube, A. (2022). Weak Association between Skin Autofluorescence Levels and Prediabetes with an ILERVAS Cross-Sectional Study. Nutrients, 14(5), 1102. https://doi.org/10.3390/nu14051102
    • Russell, S. J., Sala, R., Conaghan, P. G., Habib, G., Vo, Q., Manning, R., Kivitz, A., Davis, Y., Lufkin, J., Johnson, J. R., Kelley, S., & Bodick, N. (2018). Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. Rheumatology (Oxford, England), 57(12), 2235-2241. https://doi.org/10.1093/rheumatology/key265
    • Yang, L., Zhang, J., Ruan, D., Zhao, K., Chen, X., & Shen, W. (2020). Clinical and Structural Outcomes After Rotator Cuff Repair in Patients With Diabetes: A Meta-analysis. Orthopaedic journal of sports medicine, 8(9), 2325967120948499. https://doi.org/10.1177/2325967120948499
    • Waqas, K., Chen, J., Trajanoska, K., Ikram, M. A., Uitterlinden, A. G., Rivadeneira, F., & Zillikens, M. C. (2022). Skin Autofluorescence, a Noninvasive Biomarker for Advanced Glycation End-products, Is Associated With Sarcopenia. The Journal of Clinical Endocrinology and Metabolism, 107(2), e793–e803. https://doi.org/10.1210/clinem/dgab632

    Related reading

  • Dr. Gurpreet Singh Padda presenting beside the title card reading Your Diet Is Manufacturing Your Pain, The Pained Brain, Chapter 5

    NSAID Cardiovascular Risk in Chronic Pain: Who to Measure and Why

    Your Diet Is Manufacturing Your Pain | The Pained Brain, Chapter 5

    NSAID Cardiovascular Risk in Chronic Pain: Who to Measure and Why

    Measure daily or near-daily NSAID users with chronic pain, especially those with diabetes, hypertension, kidney disease or a metabolic phenotype. Pooled trials put major vascular events up with coxibs and diclofenac, heart failure risk roughly doubled across the class, and chronic use carried a 1.50 hazard for chronic kidney disease.

    Chronic NSAID users are an identifiable population carrying measurable vascular and renal exposure, and most of them are never assessed for it.

    NSAID cardiovascular risk is well characterized in trials and seldom measured in the individual taking the drug. The daily ibuprofen or naproxen user with chronic musculoskeletal pain appears on a medication list, receives a renewal, and rarely receives a vascular, renal or metabolic assessment tied to that exposure. The video above is Chapter 5 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, which argues that the prostaglandin pathway these drugs block is supplied by the omega-6 content of the diet. For a screening practice, that argument reduces to two questions: which chronic users should be measured, and what a finding changes.

    How much do NSAIDs raise cardiovascular risk?

    The Coxib and traditional NSAID Trialists’ Collaboration pooled individual data from 280 placebo-controlled trials and 124,513 participants. Major vascular events rose with coxibs (RR 1.37) and diclofenac (RR 1.41), roughly three additional events per 1,000 patients treated for a year, one of them fatal. Naproxen was the vascular exception (RR 0.93). Heart failure risk roughly doubled across the class, and upper gastrointestinal complications rose 3.97-fold on ibuprofen and 4.22-fold on naproxen. Those trials used high doses in selected, often high-risk populations.

    The signal is not confined to long courses. A Bayesian individual-patient meta-analysis of 446,763 people found odds ratios for acute myocardial infarction of 1.48 for ibuprofen, 1.50 for diclofenac and 1.53 for naproxen within one to seven days of use, dose-related and front-loaded rather than accumulating with duration. On the renal side, 40 studies covering 1,757,118 participants gave chronic use a pooled hazard of 1.50 for chronic kidney disease, 1.67 with pre-existing kidney disease and 1.35 in diabetes or hypertension. Confounding by indication is plausible in both datasets; it does not erase them.

    Patient behavior widens the gap between label and exposure. In a one-week diary study of 1,326 American ibuprofen users, 37 percent also took a non-ibuprofen NSAID and 11 percent exceeded the daily ibuprofen limit, with ongoing pain among the associated characteristics.

    How much do NSAIDs actually help spinal pain?

    Most of us, myself included, were trained to renew the anti-inflammatory and treat the diet as somebody else’s department. The efficacy data in spinal pain do not support that reflex. Across 35 placebo-controlled trials, only 3 of 14 comparisons cleared a ten-point minimum worthwhile difference, the number needed to treat was 6, and gastrointestinal adverse events were already 2.5 times as common in trials with a median duration of 7 days. The authors concluded that no simple analgesic gives clinically important relief for spinal pain, not that NSAIDs are useless. For the physician deciding whether to measure, the relevant point is that the risk-benefit balance in long-term users is close enough for patient-level data to carry real weight.

    Is a normal CRP enough to clear a chronic pain patient?

    A common shortcut is to check C-reactive protein and move on. The evidence behind that shortcut was generated in the wrong population. The founding systematic review of dietary linoleic acid and inflammatory markers covered 15 randomized trials in healthy adults. A later pooling of 30 trials and 1,377 participants found a CRP effect of SMD 0.09, indistinguishable from zero, with a subgroup hint of a rise at the largest intake increases. Obese, insulin-resistant and chronic pain patients were largely absent.

    In a crossover of 39 abdominally obese adults given seven weeks of marine omega-3 and seven of linoleic acid, circulating markers did not differ between treatments, yet adipose biopsies showed 334 differentially expressed genes after the omega-6 period, with inflammatory pathways up-regulated. Red-cell composition tells a parallel story: in 605 adults with chronic pain conditions, a higher arachidonic acid to EPA-plus-DHA ratio tracked higher pain intensity, cross-sectionally. The practical inference is that a normal CRP in a metabolically burdened pain patient does not clear the terrain. The population baseline is poor: 97.6 percent of US adults have a red-cell omega-3 index below 8 percent, and under 12.2 percent of US adults were metabolically healthy on NHANES 2009–2016, under 7 percent on the tighter post-2021 criteria.

    Who to measure

    A workable selection rule for primary care, pain, cardiology or geriatric practice starts from the medication list rather than from symptoms:

    • Daily or near-daily NSAID use beyond a short course, prescribed or over the counter.
    • Chronic NSAID use with diabetes, hypertension or known kidney disease, the subgroups carrying the higher renal hazards.
    • Chronic pain with a metabolic phenotype: central adiposity, dysglycemia, or the thin-outside, inflamed-inside pattern that body weight conceals.
    • Long-term use of the same agent without a documented reassessment.

    Arterial stiffness and endothelial function assesses large-artery rigidity and the vessel lining’s capacity to dilate. Its relevance here is supported indirectly, including a cross-sectional association in 346 nonsmokers between a urinary acrolein metabolite, a product of heated polyunsaturated oil among other sources, and worse endothelial function. Laboratory panels define glycemic and insulin status alongside the renal markers the prescriber already follows. Bioimpedance body composition separates the lean and fat compartments that BMI conflates. Measura [Cardiometabolic and Autonomic Health Analysis] returns findings to the ordering physician; it does not diagnose disease on its own or manage the medication.

    What a finding changes

    An abnormal vascular or metabolic result does not dictate a prescribing decision. It improves the one the treating physician makes: the risk side of the NSAID discussion gains an individual measurement instead of a population estimate, the decision about agent, dose and duration becomes documented, and patients whose kidney function deserves closer follow-up are flagged. It also opens the upstream conversation Chapter 5 is really about, correcting the lipid profile. In the book’s protocol that means measuring the red-cell omega-3 index against a target above 8 percent, removing seed oils, adding EPA and DHA, and retesting at about five months, since red-cell content took roughly that long to equilibrate in a dose-response trial of 115 healthy adults. Food-based trials support the direction: in 182 adults with migraine, a high omega-3, low omega-6 diet produced 4.0 fewer headache days a month than control, although the primary quality-of-life endpoint did not reach significance.

    Building it into workflow

    The trigger already sits in the record. A standing order keyed to chronic NSAID use on the medication list makes the screen reproducible rather than dependent on who is in clinic that day. The annual wellness visit medication review is a natural place for it to fire. Results belong in structured fields the next prescriber will see, which getting results into the record covers, and where a practice reports cardiovascular or diabetes-related quality measures, the same data support documentation under MIPS and quality reporting. The patient-facing account of the same evidence is the patient article on seed oils and inflammation; the study-by-study appraisal is on the Chapter 5 book companion page; and the glycation problem that follows is in hand and shoulder diagnoses as dysglycemia screening triggers.

    Frequently asked questions

    Is naproxen the safer choice for patients with cardiovascular risk?

    For major vascular events, naproxen was the exception in the individual-participant meta-analysis, at RR 0.93. It was not an exception for upper gastrointestinal complications, which rose 4.22-fold, and the short-term myocardial infarction analysis still found odds of 1.53 within the first week of use. Heart failure risk roughly doubled across NSAIDs. Agent selection narrows the risk; it does not remove it. Clinical rationale.

    Does a normal CRP mean dietary omega-6 is not a problem for this patient?

    Not in a metabolically burdened patient. The trials showing no CRP effect were largely conducted in healthy adults over weeks. In abdominally obese adults, seven weeks of linoleic acid left circulating markers unchanged while adipose tissue showed inflammatory gene up-regulation. CRP reports the blood compartment; the argument concerns tissue and membrane composition, which it does not see. Interpreting the report.

    Which chronic NSAID users should be prioritized for vascular testing?

    Start with daily users who also carry diabetes, hypertension or kidney disease, since those subgroups showed higher renal hazards, and with patients on diclofenac or coxibs, which carried the larger vascular signals. Ask directly about over-the-counter products taken on top of a prescription: in a diary study, more than a third of ibuprofen users also took another NSAID. Specialty applications.

    When should an omega-3 index be rechecked after a dietary change?

    At around five months. In a randomized dose-response trial of 115 healthy adults, red-cell omega-3 content took approximately that long to reach its new level, and dose alone explained 68 percent of the variability. An earlier recheck risks reading an incomplete transition as failure. Supplement pain trials also showed effects growing over time, from SMD 0.27 at one month to 0.83 at six. Chronic care and between-visit monitoring.

    How should the screen be documented?

    Record the trigger, the indication for the NSAID, the measurements obtained and the resulting decision about agent, dose or duration in structured fields. That converts a routine renewal into a documented reassessment and gives the next clinician a baseline to compare against. Quality programs reward exactly this kind of reproducible, measured process. Getting diagnostic results into the chart.

    Which NSAID has the highest cardiovascular risk?

    In pooled data from 280 placebo-controlled trials, diclofenac (RR 1.41) and the coxibs (RR 1.37) carried the largest rise in major vascular events, while naproxen did not (RR 0.93). Heart failure risk roughly doubled across the class, and within the first week of use the odds of a heart attack rose for ibuprofen, diclofenac and naproxen alike, at 1.48 to 1.53.

    Is it harmful to take ibuprofen every day?

    Daily use is the exposure this page is about. Chronic NSAID use carried a 1.50 hazard for chronic kidney disease, higher with existing kidney disease, and heart attack odds rose within days of starting. Daily users often take more than they realize: in a one-week diary study, 37 percent of ibuprofen users also took another NSAID and 11 percent exceeded the daily limit. Review dose and duration with your prescriber.

    See how the protocol fits your practice

    Learn how Measura testing can be added to your screening workflow for patients on long-term anti-inflammatory therapy, from standing orders to reporting.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet, 382(9894), 769-779. https://doi.org/10.1016/S0140-6736(13)60900-9
    • Bally, M., Dendukuri, N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., & Brophy, J. M. (2017). Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ, 357, j1909. https://doi.org/10.1136/bmj.j1909
    • Soliman, S., Ahmed, R. M., Ahmed, M. M., Attia, A., & Soliman, A. R. (2025). Non-steroidal anti-inflammatory drugs: what is the actual risk of chronic kidney disease? A systematic review and meta-analysis. Romanian Journal of Internal Medicine, 63(1), 3-27. https://doi.org/10.2478/rjim-2024-0029
    • Kaufman, D. W., Kelly, J. P., Battista, D. R., Malone, M. K., Weinstein, R. B., & Shiffman, S. (2018). Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiology and Drug Safety, 27(3), 322-331. https://doi.org/10.1002/pds.4391
    • Machado, G. C., Maher, C. G., Ferreira, P. H., Day, R. O., Pinheiro, M. B., & Ferreira, M. L. (2017). Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 76(7), 1269-1278. https://doi.org/10.1136/annrheumdis-2016-210597
    • Su, H., Liu, R., Chang, M., Huang, J., & Wang, X. (2017). Dietary linoleic acid intake and blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Food & Function, 8(9), 3091-3103. https://doi.org/10.1039/c7fo00433h
    • Grytten, E., Laupsa-Borge, J., Cetin, K., Bohov, P., Nordrehaug, J. E., Skorve, J., Berge, R. K., Strand, E., Bjørndal, B., Nygård, O. K., Rostrup, E., Mellgren, G., & Dankel, S. N. (2025). Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study. Journal of Lipid Research, 66(4), 100770. https://doi.org/10.1016/j.jlr.2025.100770
    • Flock, M. R., Skulas-Ray, A. C., Harris, W. S., Etherton, T. D., Fleming, J. A., & Kris-Etherton, P. M. (2013). Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. Journal of the American Heart Association, 2(6), e000513. https://doi.org/10.1161/JAHA.113.000513
    • McGraw, K. E., Riggs, D. W., Rai, S., Navas-Acien, A., Xie, Z., Lorkiewicz, P., Lynch, J., Zafar, N., Krishnasamy, S., Taylor, K. C., Conklin, D. J., DeFilippis, A. P., Srivastava, S., & Bhatnagar, A. (2021). Exposure to volatile organic compounds – acrolein, 1,3-butadiene, and crotonaldehyde – is associated with vascular dysfunction. Environmental Research, 196, 110903. https://doi.org/10.1016/j.envres.2021.110903
    • Ramsden, C. E., Zamora, D., Faurot, K. R., MacIntosh, B., Horowitz, M., Keyes, G. S., Yuan, Z.-X., Miller, V., Lynch, C., Honvoh, G., Park, J., Levy, R., Domenichiello, A. F., Johnston, A., Majchrzak-Hong, S., Hibbeln, J. R., Barrow, D. A., Loewke, J., Davis, J. M., … Mann, J. D. (2021). Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ, 374, n1448. https://doi.org/10.1136/bmj.n1448

    Related reading